US20230277829A1 - Applicators for microneedles - Google Patents
Applicators for microneedles Download PDFInfo
- Publication number
- US20230277829A1 US20230277829A1 US18/318,603 US202318318603A US2023277829A1 US 20230277829 A1 US20230277829 A1 US 20230277829A1 US 202318318603 A US202318318603 A US 202318318603A US 2023277829 A1 US2023277829 A1 US 2023277829A1
- Authority
- US
- United States
- Prior art keywords
- applicator
- energy
- stable configuration
- skin
- storing element
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000007704 transition Effects 0.000 claims abstract description 23
- 238000004146 energy storage Methods 0.000 claims description 76
- 239000000463 material Substances 0.000 claims description 25
- 230000007246 mechanism Effects 0.000 claims description 25
- 230000033001 locomotion Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 6
- 230000013011 mating Effects 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 81
- 238000011282 treatment Methods 0.000 description 17
- 238000003491 array Methods 0.000 description 15
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical group C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 15
- 108010049264 Teriparatide Proteins 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000010410 layer Substances 0.000 description 13
- 238000013461 design Methods 0.000 description 11
- 230000004913 activation Effects 0.000 description 9
- 229940053641 forteo Drugs 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 7
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 6
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 102000058004 human PTH Human genes 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 101100468275 Caenorhabditis elegans rep-1 gene Proteins 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- 108700012941 GNRH1 Proteins 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 101100238610 Mus musculus Msh3 gene Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 229940119743 dextran 70 Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OGBMKVWORPGQRR-UHFFFAOYSA-N forteo Chemical compound C=1NC=NC=1CC(C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(C(C)C)C(=O)NC(CC=1N=CNC=1)C(=O)NC(CC(N)=O)C(=O)NC(CC=1C=CC=CC=1)C(O)=O)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(N)CO)C(C)C)C(C)CC)CC1=CNC=N1 OGBMKVWORPGQRR-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 230000036558 skin tension Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960005460 teriparatide Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical class C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 description 1
- YGGIRYYNWQICCP-LDRBRYNMSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylamino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydrox Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 YGGIRYYNWQICCP-LDRBRYNMSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 108010010737 Ceruletide Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108010003422 Circulating Thymic Factor Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JXNRXNCCROJZFB-UHFFFAOYSA-N Di-Me ester-(2R, 3E)-Phytochromobilin Natural products NC(N)=NCCCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-UHFFFAOYSA-N 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102400001357 Motilin Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 108010012944 Tetragastrin Proteins 0.000 description 1
- 102400000159 Thymopoietin Human genes 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920006231 aramid fiber Polymers 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 229940108471 crofab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940021344 digifab Drugs 0.000 description 1
- 108010034479 digoxin antibodies Fab fragments Proteins 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000007688 edging Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 108700020627 fertirelin Proteins 0.000 description 1
- 229950001491 fertirelin Drugs 0.000 description 1
- DGCPIBPDYFLAAX-YTAGXALCSA-N fertirelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 DGCPIBPDYFLAAX-YTAGXALCSA-N 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000004761 kevlar Substances 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 229960003822 lutrelin Drugs 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 229960003873 thymostimulin Drugs 0.000 description 1
- 230000002916 thymostimulin Effects 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Definitions
- the subject matter described herein relates generally to drug delivery using microneedles or other microprojections, and more specifically to applicators for applying an array of microprojections to the stratum corneum.
- Microneedle arrays can facilitate the passage of drugs through human skin and other biological membranes in circumstances where ordinary transdermal administration is inadequate. Microneedle arrays can also be used to sample fluids found in the vicinity of a biological membrane such as interstitial fluid, which is then tested for the presence of biomarkers.
- microneedle arrays In recent years it has become more feasible to manufacture microneedle arrays in a way that makes their widespread use financially feasible.
- U.S. Pat. No. 6,451,240 discloses some methods of manufacturing microneedle arrays. If the arrays are sufficiently inexpensive, for example, they may be marketed as disposable devices. A disposable device may be preferable to a reusable one in order to avoid the question of the integrity of the device being compromised by previous use and to avoid the potential need of resterilizing the device after each use.
- An intravenous injection delivers a precise quantity of an active agent to the circulation.
- a subcutaneous or intramuscular injection delivers a precise quantity of an active agent into the tissue, but the quantity of active agent delivered to the circulation and the rate at which active ingredient is delivered are affected by the type of surrounding tissue, circulation, and possibly other factors.
- the resulting blood levels may exhibit substantial variation among patients due to metabolism and other factors, but minimal therapeutic levels can be assured for most patients, for example, because the rate of metabolism has an upper limit and because there is long experience with the absorption of many drugs from oral formulations.
- Microneedles manipulate the permeability of the skin with respect to the active agent. Variability in the permeability enhancement created by different applications of the microneedles will result in variations in the rate of transfer through the skin, the amount transferred through the skin and the bioavailability. Variability of skin permeability enhancement on the application of a microneedle array can result from application on different patients. Particular concern exists, of course, if the enhancement is small in particular patient populations so that the administration of the drug will not produce a therapeutically effective dosing (e.g., adequate blood levels) in those populations. Concern may arise also if the enhancement is sometimes undesirably small in a patient, even if at other times the enhancement is as expected in that patient, depending on details of how and where the microneedle array is applied.
- a typical microneedle array comprises microneedles projecting from a base of a particular thickness, which may be of any shape, for example square, rectangular, triangular, or circular.
- the microneedles themselves may have a variety of shapes.
- an array could be pressed by hand into skin, it has also been proposed to use a variety of devices to hold the microneedle array as it is being applied or to facilitate in one way or another the process of microneedle array application to the skin or other biological membrane.
- Such devices may broadly be referred to as “applicators.” Applicators may for example reduce the variations in force, velocity, and skin tension that occur when a microneedle array is pressed by hand into the skin. Variations in force, velocity and skin tension can result in variations in permeability enhancement.
- microneedle arrays may be applied to the skin or other biological membrane in order to form microchannels and then are more or less immediately withdrawn. In other applications the microneedle array may be held in place for a longer period of time.
- the design of the applicator may naturally be influenced by how long the microneedles are expected to stay in place.
- Applicators for microneedles comprising components which have two stable states have been described in U.S. Published Patent Application No. 2008/0183144.
- the existence of two stable states is a feature generally desired in an applicator because the energy difference between the two stable states can allow each use of the applicator to employ a fixed amount of energy in order to cause penetration, improving reproducibility.
- a limitation of this earlier approach is that the energy delivered to the microstructure array is both limited and variable. The earlier approach was dependent on the input of the user for both energy and velocity, and variation in application technique had a significant effect on the ability of the device to enhance the permeability of the skin.
- the energy storage element such as a spring or elastic element
- the energy storage element may exert forces on one or more components of the applicators, leading to dimensional distortion and creep over an extended period of time. These effects are undesirable as they lead to variations in the applicator geometry and a loss in the stored elastic energy over time. Therefore, there is a need for an applicator which has energy storage elements that do not exert forces on one or more components of the applicator.
- microneedle arrays particularly when the arrays are kept in place for a prolonged period of time, devices to transport the drug substance to the skin may be employed.
- a very simple such device may, for example, comprise a reservoir for liquid or solid drug substance which is kept in contact with the base, with the liquid drug substance flowing through small apertures in the base or by diffusion when solid drug substance is used.
- Another device suitable for delivering the drug substance to skin is described in U.S. Published Patent Application No. 2005/0094526.
- Rotary applicators have been disclosed in U.S. Published Patent Application No. 2004/0087992. There is some disclosure relating to applicators, for example, in U.S. Pat. Nos. 6,537,242, 6,743,211 and 7,087,035.
- an applicator for a microprojection array comprises an energy-storing element which has a first stable configuration and second stable configuration, wherein application of force can cause the energy-storing element to transition from the first stable configuration to the second stable configuration, and wherein the force necessary for the energy storing element to transition from the first stable configuration to the second stable configuration is lower than the force necessary for the element to transition from the second stable configuration to the first stable configuration.
- the applicator also comprises an actuating member that can convey external force to the energy-storing element, a microprojection-holding member connected to the actuating member and which is acted on by the energy-storing element when it transitions from the first stable configuration to the second stable configuration, an outer cover with an opening into which the actuating member fits slidably, and a skin-contacting member comprising a portion which can lie flat against skin, wherein the skin-contacting member fits the outer cover and contacts the energy-storing element when it is in its first configuration.
- the energy-storing element has an axis of symmetry and n-fold rotational symmetry for some integer n.
- application of force to the energy-storing element in a direction of its axis of symmetry causes it to transition from the first stable configuration to the second stable configuration.
- an applicator for a microprojection array comprises a housing having a surface with an elongated opening having platforms on opposite sides of the opening.
- An actuation member comprising a surface upon which a microprojection array can be attached, a generally washer-shaped surface on which an energy-storage member can be placed, and a surface capable of mating with the platforms on the opening of the housing and capable of fitting through the opening is included.
- An energy-storage member is situated between the actuation member and the housing, and a skin-contacting area which is generally washer-shaped is connected to the housing.
- the energy-storage member when the actuation member is mated with the platforms on the opening, the energy-storage member is compressed, and when the actuation member is moved within the opening so that it no longer mates with the platforms, the energy-storage member is free to expand and in so doing moves the actuation member.
- the energy-storage member is in the form of a wave spring.
- the energy storage member has an n-fold rotational axis of symmetry of between about 3-22, more preferably 3-18 or 3-9, and still more preferably between 3-6.
- the actuator member moves within the outer cover between a first position and a second position, wherein in its first position the actuator member extends outwardly from and beyond an upper surface of the outer cover.
- the actuator member moves within the outer cover between a first position and a second position, wherein in its first position the actuator member is recessed within the outer cover.
- the microprojection array is attached to the microprojection-holding member, the microprojection array comprises a base, and the level of the microprojection array's base is below a skin-contacting surface of the skin-contacting member following actuation of the actuating member.
- the level of the microprojection array's base below the skin-contacting surface of the skin-contacting member is between about 0.001 inches to about 0.200 inches, more preferably between about 0.001 inches to about 0.125 inches, still more preferably from about 0.030 inches to about 0.090 inches.
- the energy-storing element is in mechanical coupling relationship with the microprojection-holding member when the energy-storing element is in its first stable configuration.
- an applicator for a microprojection array comprises (a) a housing having a surface with an elongated opening having platforms on opposite sides of the opening; (b) an actuation member comprising a surface upon which a microprojection array can be attached, a generally washer-shaped surface on which an energy-storage member can be placed, and a surface capable of mating with the platforms on the opening of the housing and capable of fitting through the opening; (c) an energy-storage member situated between the actuation member and the housing; and (d) a skin-contacting area which is generally washer-shaped connected to the housing.
- the energy-storage member When the actuation member is mated with the platforms on the opening, the energy-storage member has a first force of stored energy, and when the actuation member is moved within the opening so that it no longer mates with the platforms, the energy-storage member releases its stored energy and in so doing moves the actuation member.
- the energy-storage member when mated with the platforms on the opening has a first force of stored energy by virtue of its being compressed.
- an applicator comprises (a) a housing having a first member with a central opening and a second member having a skin contacting surface; (b) an actuation member disposed in the central opening and comprising a surface upon which a microprojection array can be attached and a groove extending circumferentially; and (c) an energy-storage member having an inner edge and an outer edge, and situated within the housing initially in a first stable configuration such that the inner edge is disposed in the groove and its outer edge is in contact with the second member. Application of force to the actuation member moves the energy-storage member from its first stable configuration to a second stable configuration wherein the outer edge is no longer in contact with the second member.
- the outer edge of the energy storage member in its second stable configuration is in contact with the first member.
- a microprojection array holder engages the actuation member, the engagement of the actuation member and the microprojection array holder defining the groove.
- the energy-storage member has an axis of symmetry and n-fold rotational symmetry for some integer n, wherein application of force in a direction of the axis of symmetry causes the energy-storing element to transition from the first stable configuration to the second stable configuration, and wherein the force necessary for the energy storing element to transition from the first stable configuration to the second stable configuration is lower than the force necessary for the element to transition from the second stable configuration to the first stable configuration.
- the energy-storing element is of generally frustoconical shape with slots from the top of the frustum, from the bottom of the frustum, or from both.
- any of the applicator embodiments described herein further comprises a safety mechanism to prevent movement of the actuation member in a direction that deploys the microprojection array.
- the safety mechanism comprises a protective cap over the applicator housing. In another embodiment, the safety mechanism comprises a pin movably inserted into the actuation member on an applicator.
- a device comprising an applicator in accord with any of the aspects and embodiments described herein and a microprojection array comprising an active agent is provided.
- a method for applying a microprojection array to a biological barrier comprises providing an applicator as described herein, the applicator including or capable of including a microprojection array.
- the applicator is contacted with the biological barrier, and an actuating member on the applicator is activated, to initiate movement of the energy-storage member from its first stable configuration to its second stable configuration. Movement of the energy-storage member induces movement of the microprojection array, directly or indirectly, causing it to forcibly contact the biological barrier.
- the microprojection array comprises a therapeutic or prophylactic agent
- the method achieves administration of the agent to a subject.
- FIGS. 1 A- 1 C are views of an applicator as described herein, the applicator shown in perspective views ( FIG. 1 A ), a sectional view ( FIG. 1 B ) and an exploded view ( FIG. 1 C ).
- FIGS. 1 D- 1 E show the applicator of FIGS. 1 A- 1 C in perspective view ( FIG. 1 D ) and in a cross-sectional view ( FIG. 1 E ) after actuation of its actuating member.
- FIGS. 1 F- 1 T are perspective views of embodiments of energy-storage elements for use in an applicator as described herein.
- FIGS. 1 U- 1 V illustrate movement of an energy-storage element between its first stable configuration and its second stable configuration.
- FIG. 2 A depicts schematically, with certain dimensions exaggerated for clarity, an applicator.
- FIG. 2 B depicts schematically, with certain dimensions exaggerated for clarity, one quarter of the push member of the applicator of FIG. 2 A .
- FIGS. 3 A- 3 B depict schematically another embodiment of an applicator, where in FIG. 3 A a schematic cross-section of one half of the applicator is shown, and in FIG. 3 B a perspective view of a particular component is shown.
- FIG. 4 A shows an exploded view of another embodiment of an applicator.
- FIG. 4 B shows a perspective view of the same applicator.
- FIG. 5 depicts an alternative outer member for the applicator of FIGS. 4 A- 4 B .
- FIGS. 6 A- 6 B illustrate a cantilevered pin safety mechanism to prevent unintentional deployment of an activator.
- FIGS. 7 A- 7 B illustrate another embodiment of a safety mechanism to prevent unintentional deployment of an activator.
- FIGS. 8 A- 8 B illustrate an example of tab safety mechanisms to avoid accidental actuation of an actuation member in an applicator.
- FIGS. 9 A- 9 C illustrate another embodiment of a safety mechanism, where a protective cap is shown in a closed position ( FIG. 9 A ) and in an open position ( FIG. 9 B ), and disposed in place on an applicator ( FIG. 9 C ).
- FIGS. 10 A- 10 B illustrate another embodiment of a cap type safety mechanism.
- FIGS. 11 A- 11 B are perspective views of an applicator according to yet another embodiment, wherein FIG. 11 A depicts the applicator in a configuration prior to deployment or actuation by a user, and FIG. 11 B depicts the same applicator after deployment or actuation by a user.
- FIGS. 12 A- 12 B are cross-sectional side views of a first embodiment of internal components of an applicator according to the applicator of FIGS. 11 A- 11 B , wherein FIG. 12 A depicts the applicator in a configuration prior to deployment or actuation by a user, and FIG. 12 B depicts the same applicator after deployment or actuation by a user.
- FIGS. 13 A- 13 B are cross-sectional side views of a second embodiment of internal components of an applicator according to the applicator of FIGS. 11 A- 11 B , wherein FIG. 13 A depicts the applicator in a configuration prior to deployment or actuation by a user, and FIG. 13 B depicts the same applicator after deployment or actuation by a user.
- an active ingredient includes a plurality of active ingredients as well as a single active ingredient
- a temperature includes a plurality of temperatures as well as single temperature, and the like.
- microprotrusions as the type of microprotrusion or microprojection which is being employed. It will be understood by persons of skill in the art that in many cases the same inventive principles apply to the use of other microprotrusions or microprojections to penetrate skin or other biological membranes.
- Other microprotrusions or microprojections may include, for example, microblades as described in U.S. Pat. No. 6,219,574 and Canadian patent application no. 2,226,718, and edged microneedles as described in U.S. Pat. No. 6,652,478.
- the term “downward” is sometimes used to describe the direction in which microprotrusions are pressed into skin, and “upward” to describe the opposite direction.
- the applicators can be used where the microprotrusions are pressed into skin at an angle to the direction of the earth's gravity, or even in a direction contrary to that of the earth's gravity.
- the energy for pressing the microprotrusions is provided primarily by an energy-storage member and so efficiency is not much affected by the orientation of the skin relative to the earth's gravity.
- microneedles and other microprotrusions for use with the applicators described herein will be a function of the manufacturing technology and of the precise intended application (e.g., the active agent to be delivered, whether it is contained in the microprojections, etc.).
- microneedles and other microprotrusions used in practice may be expected to have a length of about 20 to about 1000 microns, more preferably from about 50 to about 750 microns and most preferably from about 100 to about 500 microns.
- the microprotrusions will be long enough to penetrate through the stratum corneum layer of skin at some suitable point of application on the human body, for example the thigh, hip, arm, or torso.
- microneedle array for purposes herein is intended to denote a two-dimensional or a three-dimensional arrangement of microneedles. The arrangement may be regular according to a repeating geometric pattern or it may be irregular. Similarly, “microprojection array” denotes a two-dimensional or three-dimensional arrangement of microprojections.
- an applicator for microprojection arrays in which the velocity at the time of microprojection array contact with skin is controlled within a predetermined range.
- the applicator operates when an actuating element is pressed with a force which is above a threshold.
- the velocity of contact is substantially independent of the precise force employed to press the actuating element.
- the applicator comprises an energy-storing element.
- a method for inserting microprojections in an array of microprojections into skin or another biological barrier comprises placing an applicator in contact with the barrier into which the array is to be inserted and operating an actuating element which forms part of the applicator with a force which lies above a predetermined threshold.
- the velocity of the microprojection array and the energy per microstructure at the time of contact with skin need to be above a threshold and may be controlled within a predetermined range.
- Applicators contemplated herein will commonly have two states or configurations.
- the applicator In the first state or configuration, the applicator has the microprojection array recessed. This is expected to be the state of the applicator following manufacturing and during shipping and storage.
- the second state or configuration In the second state or configuration, which is arrived at by pressing or otherwise operating the actuating element, the microprojection array projects modestly outward from the applicator.
- the velocity of the microprojection array at the time of contact with skin may be adjusted, for example, by varying the amount of stored energy in the energy-storing element. This is done, for example, by controlling the energy-storing element's geometric design and the properties of the material(s) out of which the energy-storing element is made.
- the energy-storing element may have a compressed form in which the degree of compression (e.g., in one spatial direction) controls the amount of energy stored.
- the energy storing element When the energy storing element is stored in compressed form, a variety of mechanisms external to the element, but forming part of the applicator, may be employed to release the compression and allow the element to uncompress and therefore release some or all of its energy.
- the energy-storing element may be bistable in that it has two stable states in which energy is stored.
- the two states may have different energies.
- the amount of stored energy may be, for example, in the range of about 0.1 J to about 10 J, or in the range of about 0.25 J to about 1 J.
- the energy storage element having two bi-stable states is highly advantageous because in its higher energy state, the energy storage element does not exert any significant forces on the applicator components, thereby alleviating the problems with dimensional distortion and creep over time. Reducing the dimensional distortion and creep lead to maintaining the same stored elastic energy for an extended period of time. Maintaining the same stored elastic energy over a period of time is important for having an extended shelf life of at least preferably 6 months, more preferably 12 months, and most preferably 24 months.
- the velocity of the microprojection array at the time of contact with the skin may lie, for example, within the range of 0.1 m/s to 20 m/s, or within the range of 0.5 m/s to 10 m/s.
- the stored energy may be employed in moving the microprojection array into contact with the skin as well as in overcoming any forces (e.g., from other components of the applicator) acting on the microprojection array.
- the stored energy may be employed in moving other components which, in accordance with the design of the applicator, must also move as the microprojection array moves towards the skin.
- the velocity of the microprojection array is preferably reproducible.
- the standard deviation of the velocity in a number of applications carried out with different applicators of the same design or by different persons using the same applicator may be less than about 10% of the average velocity, less than about 5%, or less than about 1%.
- the applicator comprise one or more components which have rotational symmetry about an axis perpendicular to the microprojection array.
- n n-fold rotational symmetry
- the clip depicted in FIG. 3 B a component of an applicator described herein, has 3-fold rotational symmetry.
- the energy-storing element be in mechanical coupling relationship with the microprojection array or a member holding the array at all times.
- An alternative design would allow the energy-storing element not to be coupled to the microprojection array during the stored state of the applicator but only to come into contact with the array or a member holding the array during the process of actuation. Such contact may occur at a nonzero velocity, although it is desirable that this nonzero velocity be low, for example below about 0.1 cm/s, or below about 0.25 cm/s or below about 1 cm/s.
- microneedle array may then settle, pressed by the applicator, into the skin at a level which is modestly below the original level of the skin.
- the force with which the microprojection array is pressed into the skin may be, for example, between about 0.1 and about 10 N/cm 2 .
- the level of the microprojection array's base below the skin is about 0.001 inches (0.00254 cm) or greater, and in other embodiments is between about 1/16 inch (0.0625 inches or 0.159 cm) and about 3/16 inch (0.188 inches or 0.476 cm), or between about 1/16 inch (0.0625 inches or 0.159 cm) to about 1 ⁇ 8 inch (0.125 inches or 0.318 cm).
- the applicator has a primary member, which is contacted with skin when the applicator is to be used.
- the microprojection array is attached to a retaining member which holds the energy storage device in compression.
- the retaining member is held in place by a flexible mechanism.
- the actuation mechanism causes the flexible mechanism to be displaced or elastically deformed in such a way that the retaining member ceases to be restrained.
- the energy-storage device is then free to expand or to move between first and second configurations, moving the retaining member, and the microprojection array is then displaced towards the skin.
- FIGS. 1 A- 1 C depict several views one possible arrangement of an applicator 10 .
- the applicator comprises a skin contacting element 12 which has an opening 14 in its center, and, in this embodiment, has complete rotational symmetry.
- Skin-contacting element 12 mates with an applicator housing 16 which, in this embodiment, also has complete rotational symmetry and is manufactured from a rigid material (e.g., a polymeric, filled polymeric, composite, or metal material) which preferably does not visibly flex during operation of the device).
- a rigid material e.g., a polymeric, filled polymeric, composite, or metal material
- the housing can also be semi rigid, semi-flexible, or flexible, if desired.
- Housing 16 has an opening 18 at the top, through which an actuating member 20 slidingly fits. As seen best in FIG.
- a holder 24 which holds a microprojection array (which is not shown in FIGS. 1 A- 1 C ).
- a groove 26 is defined which again has complete rotational symmetry.
- a bistable energy-storage member 28 having an approximately frustoconical form has an inner edge 30 positioned within groove 26 .
- the energy-storage member of this embodiment is referred to herein as a “slotted spring”, described in further detail hereinbelow.
- FIGS. 1 D- 1 E illustrate the applicator after actuation of actuating member 20 .
- Housing 16 and its lower portion with skin contacting element 12 are shown in FIG. 1 D , where actuating member 20 is not visible because it has been depressed and is fully retained within the housing. Extending slightly beyond the skin contacting element 12 is the bottom surface of the actuating member on which an array of microprojections is held.
- FIG. 1 E is a cross-sectional view taken along line A-A in FIG. 1 D , where the actuating member contained within the housing is visible. Also visible is the configuration of the slotted spring member 28 where its inner edge 30 is in a second position relative to it is position prior to actuation, as depicted in FIG. 1 B . Specifically, inner edge 30 of the energy-storage member is at a horizontal plane that approaches or approximates the horizontal plane of the edge of the slotted spring prior to use. This transition and inversion of the spring element are described in more detail below.
- the materials from which the applicator components are manufactured can be selected from a wide variety known to a skilled artisan.
- a filled polymer material is suitable for manufacture of the outer cover, the actuating member and/or the microprojection holding member.
- a skilled artisan will understand the various material properties to be considered when selecting a suitable material for each component part.
- FIGS. 1 F- 1 G are perspective views of two different embodiments of energy-storage members for use in an applicator as described herein, such as that depicted in FIGS. 1 A- 1 E .
- Energy-storage member 40 of FIG. 1 F is substantially in the shape of a washer, and more specifically approximately a frustoconical shape.
- Inner rim 42 of the member and outer rim 44 of the member define a disc region 46 .
- Upper slots, such as upper slots 48 , 50 are cut into the disc region.
- Lower slots, such as lower slots 52 , 54 are cut into the disc region from the outer rim 44 .
- the upper and lower slots are offset from one another, so that a lower slot is positioned between adjacent upper slots, and vice versa.
- the slots serve to reduce strain of the material during its movement between its first and second stable configurations, as will be described.
- FIG. 1 G illustrates an alternative embodiment of an energy-storage member 60 .
- Energy-storage member 60 of FIG. 1 G is substantially in the shape of a washer, and more specifically a frustoconical shape.
- Inner rim 62 of the member and outer rim 64 of the member define a disc region 66 .
- a plurality of slots, such as slots 68 , 70 are cut into the disc region. The slots serve to reduce strain of the material during its movement between its first and second stable configurations, as will be described.
- the energy-storage members of the present applicator are movable between first and second stable configurations.
- the inner edge (or rim) of the energy-storage member lies in a first horizontal plane 72 and the outer edge (or rim) of the energy-storage member lies in a second horizontal plane 74 that is lower than the first horizontal plane, as depicted in FIGS. 1 U- 1 V .
- Application of force to the energy-storage member causes movement to a second stable configuration, where the inner edge of the energy-storage member approaches the second horizontal plane and the outer edge of the energy-storage member approaches the first horizontal plane.
- the relative positions of the inner rim and outer rim invert as the member transitions from a first to a second stable configuration, and back.
- the force for movement from the first stable configuration to the second stable configuration is less that the force needed to move the member from the second stable configuration to the first stable configuration. In one embodiment, a force of at least 10% greater, preferably 20% greater, still more preferably 30% greater is needed to transition the member from its second stable configuration to its first stable configuration.
- the energy-storage member as an axis of symmetry with an n-fold rotational symmetry for n, where n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In a preferred embodiment, n is between 3-18, preferably between 3-12, still more preferably between 3-9.
- the slotted spring embodiment of FIG. 1 G has an axis of symmetry with a 9-fold rotational symmetry.
- the energy-storage member is stable in both its first and second configurations, wherein stable intends that the member does not transition between first and second configurations except upon application of external force.
- the force to move from a second configuration to a first configuration is different, e.g., greater, than the force needed to move from a first configuration to a second configuration.
- FIGS. 1 H- 1 T A skilled artisan will appreciate the wide variety of energy-storage members that would be suitable for use, and examples are illustrated in FIGS. 1 H- 1 T .
- the embodiments shown, with the exception of FIGS. 1 R and 1 S have an axis of symmetry.
- Several of the embodiments have an 9-fold rotational symmetry, for example, the embodiments of FIGS. 1 K and 1 L .
- Other embodiments have a 6-fold rotational symmetry, for example, the embodiments of FIGS. 1 H, 1 J, 1 M and 1 T .
- other similar shapes including but not limited to other axisymmetric shapes, may be used to create an energy-storage member with two stable configurations.
- non-symmetric shapes may be used to create an energy-storage member with two stable configurations. It is also to be understood that the presence or absence, size, shape, and configuration of any slots or cutouts in the energy-storage member may be altered to allow the energy-storage member to have two stable configurations. It is also to be understood that the energy-storage member may comprise a plurality of individual energy-storage members that may or may not be identical in size, shape, and material. The usage of a plurality of individual energy-storage members is useful to allow alteration of applicator velocity, energy, activation force, or other performance characteristics in ways that may not be achievable with a single energy-storage member.
- an applicator comprising an energy-storage element is placed in contact with the skin such that skin contacting element 12 is directly on the stratum corneum and, optionally, adhered to skin by means of adhesive disposed on element 12 .
- the energy-storage element is in a first stable configuration and is movable to a second stable configuration by application of force.
- Actuating member 20 is pressed downward, in the direction of arrow 32 .
- the process of inversion of energy storage member may be quite rapid, appearing for example instantaneous to the human eye. It may last, for example, no more than about 10 ms, no more than about 30 ms, or more than 100 ms, or no more than 1 ⁇ 2 second.
- the shape assumed by energy storage member following inversion may be the reflection of the original shape in a plane.
- the material from which the energy storage member is manufactured is variable, and a skilled artisan will appreciate that it is selected based on the several design considerations, including storage life and desired application force, which of course will also depend on the configuration of the member.
- Exemplary materials include metals, alloys, plastics, and specific examples include stainless steel and thermoplastics.
- FIG. 2 A depicts schematically in cross-section, with certain dimensions exaggerated for emphasis, another embodiment of an applicator, prior to actuation.
- Applicator 100 comprises three principal members, an actuator 102 , a housing 104 , and a push member 106 .
- Housing 104 comprises a distal edge 108 contoured for contact with skin 110 .
- Housing 104 also has at least two projections extending from its inner circumferential surface, such as projections 112 , 114 . In other embodiments, the number of projections is 3, 4, 5, 6, 7, 8 or more.
- Each projection mates with a matching projection that extends from push member 106 , where FIG. 2 shows matching projection 116 mating with projection 112 .
- Collectively the projections hold push member 106 and resist the force of a spring 118 tending to push the push member 106 down.
- Member 106 has a planar base surface 120 onto which a microprojection array 122 is affixable or affixed.
- actuating member 102 contains for each of the projections such as 112 and 114 a rod, such as rods 124 , 126 .
- the rod by pressing down on the matching projections causes the projection to flex inward and to escape from contact with its matching projection, such as matching projections 112 , 114 . Having moved past those projections, member 106 is no longer held up by them, and the spring 118 is free to release its energy in order to move member 106 downward.
- FIG. 2 B depicts schematically one quarter of member 106 . It is seen that this quarter has a base 130 , a wall 132 , a central column 134 and a projection 136 , which is designed to engage with a projection on the applicator housing, such as projection 112 seen in FIG. 2 A .
- FIGS. 2 A- 2 B as indicated above the dimensions are exaggerated for clarity. In reality the projections on members 104 and 106 might be smaller than depicted in the figures so as not to require so great a flex inwards when the actuation member 102 is pressed down. It would be expected that all three members 102 , 104 and 106 would be composed primarily of flexible polymers or rigid polymers (including reinforced polymers). Possible materials include polycarbonate, polyetheretherketone (PEEK), polyethylene, polypropylene, polyethylene terephthalate, or other polymeric material. Fillers added to the polymer during manufacture can include glass fibers, Kevlar fibers, aramid fibers, metal fibers, carbon fibers or other polymeric filler material.
- PEEK polyetheretherketone
- Fillers added to the polymer during manufacture can include glass fibers, Kevlar fibers, aramid fibers, metal fibers, carbon fibers or other polymeric filler material.
- filler materials serve the purpose of carrying additional loads within the polymeric matrix such that the mechanical loading experienced by the polymer in the applicator parts is distributed between the polymer itself, and the filler.
- the use of fillers within the polymer reduces the dimensional distortion on the applicator parts if they experience any mechanical loading.
- the polymer and fillers also minimize creep due to less force experienced by the polymer itself. Reducing the dimensional distortion and creep lead to maintaining the same stored elastic energy for an extended period of time. Maintaining the same stored elastic energy over a period of time is important for having an extended shelf life of preferably at least 6 months, more preferably 12 months, and most preferable 24 months.
- These materials and characteristics described herein may also be used for other parts of the applicator to increase mechanical strength and stability, and reduce dimensional distortion and creep.
- FIG. 2 A Many variations on FIG. 2 A are possible.
- the number n of projections like 112 and 114 around the inner periphery of member 104 could be varied. They would generally be expected to be placed at positions 360/n degrees apart, but it might be desired to space them more closely in some instances, for example with four projections at 0 degrees, 80 degrees, 180 degrees, and 260 degrees.
- the skin-contacting edge 108 of housing 104 could be provided with a skirt so that the area which contacts the skin is more extensive.
- the skin-contacting edge could be provided with an adhesive, which in turn would in storage conveniently be covered by an optional release liner.
- the energy needed to actuate is that required to flex inward the projections, such as projections 116 ( FIG. 2 A ) or 136 ( FIG. 2 B ) of member 106 .
- This energy depends on their precise dimensions and the material characteristics (e.g., Young's modulus) of the material out of which they are made. If this pressure were sufficiently low that inadvertent actuation were a possibility, it might be desirable to place some kind of spring or spring-like object between the actuating member and the push member, so that an energy needed to deform this object must be supplied before actuation can occur.
- the use of such an object allows the user input force to be set at a level suitable for the target population without imposing limitations on the energy stored in the spring used to propel the microneedle array.
- FIGS. 2 A- 2 B it is possible to use features in addition to or different from the projections to hold a push member and spring in place prior to actuation.
- a design of this type is depicted in FIGS. 3 A- 3 B .
- FIG. 3 A which is a schematic cross-section, is a member 164 which makes contact with skin.
- a clip 168 which is depicted also in perspective in FIG. 3 B .
- Clip 168 has a certain number of outward projections, such as projection 172 . In the embodiment shown, there are three such outward projections. These outward projections may generally flex in an approximately radial direction towards the center of clip 168 . These outward projections fit into openings in member 164 as shown in FIG. 3 A .
- Spring 170 serves as an energy-storing member. It tends to push member 166 downward. However, it is restrained by the projections like 172 of clip 168 .
- an actuation member 160 In contact with clip 168 is an actuation member 160 . It has openings like 162 , one for each of the outward projections like 172 . The lower portions of these openings like 162 have a surface against which the projections like 172 press during storage. However, when actuation member 160 is pushed downwards, eventually the projections like 172 are enabled to flex outwards, releasing member 166 and allowing spring 170 to push member 166 downwards towards the skin.
- Springs of different kinds may be used to establish a minimum force which is necessary to push down member 160 and actuate the applicator.
- Such springs may, for example, be located between the upper surface of member 164 and the lower (inner) surface of actuation member 160 .
- the clip 168 may be made of metal, while the remainder of the applicator is made of suitable polymers. By making the clip of metal, the vertical wall of the housing may be made thinner, a thick section on that wall not being needed to avoid creep. As may be seen from the description above, the projections 172 in this embodiment extend further outward than the position shown in FIG. 3 A , so that some force is required to push them in enough to fit the bottom of the opening 162 in housing 160 as shown in FIG. 3 A .
- FIGS. 4 A- 4 B schematically disclose another embodiment of an applicator 180 , shown fully assembled in FIG. 4 A and in exploded view in FIG. 4 B .
- An outer housing 182 is separated by an energy-storage member 183 from a microprojection-holding member 184 which holds a microprojection array (not shown in the figure).
- the energy-storage member is in the form of a wave spring, as illustrated in FIG. 4 B .
- a wave spring is preferred in some embodiments over other types of compressive springs due to its small size when compressed, which is of value for a disposable device. It is to be understood that other compressive springs are also suitable and the applicator of this embodiment is not limited to a wave spring.
- microprojection-holding member 184 In storage, microprojection-holding member 184 is held in place by two platforms in housing 182 , such as platform 196 , against which a projection member, such as members 185 , 187 in member 184 , engages.
- a projection member such as members 185 , 187 in member 184
- a user twists member 184 (e.g., with thumb and forefingers gripping projection members 185 , 187 ) so that it is no longer over the platforms and restrained by them.
- member 184 moves downward pressing the microprojections against the skin.
- the applicator of FIGS. 4 A- 4 B is further provided with a set of components for adapting to skin, in this case an adapter 190 , a snap ring 186 , and an extender 188 .
- This extender has the same function as the outwardly projecting flange seen in FIG. 3 A as part of member 164 .
- FIG. 4 A shows an adhesive 192 and a release liner 194 .
- the applicator of FIGS. 4 A- 4 B also includes an optional safety feature, in this embodiment in the form of a pin 197 that is removably inserted through a cavity in microprojection holding member 184 prior to use. To enable the applicator for actuation, a user pulls pin 197 from its retaining position as shown in FIG. 4 A to permit a user to activate the applicator by the twisting motion described above.
- the extender 188 of the applicator may have a frustoconical rather than a flat shape.
- housing 220 comprises a base surface 222 with a projection 224 designed for contact with skin when in use.
- An outer portion 226 of the projection 224 has a thickness less than an inner portion 228 .
- Reinforcing elements, such as element 230 are provided.
- there is an elongated opening 232 at the top of housing 220 where the opening comprises two platforms, such as platform 234 , against which the microprojection-holding member presses when the applicator is in storage.
- a feature of merit for applicators is the skin penetration efficiency achieved with a particular microprojection array.
- An exemplary test for skin penetration efficiency requires the placement of the microneedle array upon a test sample of cadaver skin, the insertion of the array the applicator under testing, and the withdrawal of the array after a period of time. At that time the percentage of openings in the skin sample that are deemed to allow adequate transport of material may be taken as a figure of merit.
- a material that may be used to test adequacy of transport is India ink. It is desirable that at least about 80%, preferably at least about 90%, and more preferably at least about 95% of the openings in the skin allow adequate transport of material.
- the applicators described herein above can optionally include a safety mechanism or latch to prevent unintended actuation of the applicator and consequential deployment of the microneedle array.
- a safety mechanism or latch to prevent unintended actuation of the applicator and consequential deployment of the microneedle array.
- FIGS. 6 A- 6 B illustrate a cantilevered pin safety mechanism, where a retaining member 300 is dimensioned to snap fit on an applicator housing.
- Retaining member 300 is shown in FIG. 6 A positioned on an applicator housing, and is shown alone in an enlarged side view in FIG. 6 B .
- One or more pins, such as pin 302 , on the retaining member fit within a groove in the actuation member of an applicator, preventing deployment of the actuation member. Rotation of the retaining member in a clockwise or counterclockwise direction by pressing on tab 304 releases the pin from the retaining groove, to allow deployment of the actuation member.
- FIGS. 7 A- 7 B Another example of a pin-type safety mechanism is illustrated in FIGS. 7 A- 7 B .
- Applicator 310 comprises a housing 312 and an actuation member 314 movably inserted into an opening in housing 312 .
- a slot 316 is formed in actuation member 314 at a position where the slot is in movable engagement with a pin 318 .
- actuation member 314 is in a locked position.
- a twisting motion of the housing or the actuation member unlocks the pin and slot, so that the actuation member can be deployed.
- FIGS. 8 A- 8 B illustrate other examples of tab safety mechanisms, where in FIG. 8 A a cantilevered push tab 320 is movable to displace a pin 322 that locks an actuation member 324 in place.
- FIG. 8 B shows a twist tab or snap tab 326 that interferes with movement of the actuation member 328 . Removing the twist tab by twisting until it breaks off releases the safety mechanism and allows actuation of the applicator.
- a safety mechanism in the form of a protective cap is provided, to prevent inadvertent actuation of an applicator comprising a microneedle array.
- FIGS. 9 A- 9 B An example is provided in FIGS. 9 A- 9 B , where cap 350 is shown in a closed position ( FIG. 9 A ) and in an open position ( FIG. 9 B ).
- Cap 350 comprises a retaining member 352 and a cup member 354 connected to the retaining member by a flexible bridge member 356 . Barbs or hooks extend from the retaining member, to fix the cap onto an applicator, as depicted in FIG. 9 B .
- the cup member shields an actuation member on the applicator, preventing inadvertent application of force to the actuation member, and consequential deployment of the microneedle array.
- FIGS. 10 A- 10 B illustrate another embodiment of a cap type safety mechanism, where a peel cap 360 fits snugly about the outer periphery of an applicator, preventing access to the actuation member of the applicator. Removal of the peel cap exposes the actuation member, rendering it available for use.
- the applicator described herein is designed to prevent unintended actuation of the applicator and consequential deployment of the microneedle array in accord with the design depicted in FIGS. 11 A- 11 B .
- FIG. 11 A depicts an applicator 400 in a configuration prior to deployment or actuation by a user.
- FIG. 11 B depicts the same applicator after deployment or actuation by a user.
- Applicator 400 is comprised of a rigid housing 402 comprised of a first member 404 and a second member 406 .
- the housing is semi-rigid, semi-flexible, or flexible.
- First and second members are configured to engage one another so as to fit together in a secure configuration, such as by a snap-fit mechanism or an insertable lip/groove mechanism (seen, for example, in FIG. 12 A ).
- First member or upper housing member 404 has a central opening 408 in which an actuating member 410 slidingly fits.
- Second member or skin contacting member 406 is hollow or open, to receive the actuating member upon actuation of the applicator, as seen in FIG. 11 B .
- the plane of the top surface of actuating member denoted by dashed line 412 in FIG.
- FIGS. 12 A- 12 B are cross-sectional views of an exemplary applicator.
- the external, upper surface of the actuating member is co-planar with the uppermost surface of the housing, so that the actuating member is nested into or recessed into the housing prior to its actuation.
- the actuating member After actuation of the actuating member, wherein the actuating member is deployed to a second position, the actuating member is depressed into the housing and the upper surface of the actuating member approaches a plane defined by an upper rim of the second housing member 406 , denoted by dashed line 416 in FIGS. 12 A- 12 B .
- the design wherein the actuating member is nested into the housing prior to actuation e.g., the actuating member does not extend outward from the housing) prevents inadvertent deployment of the applicator.
- FIGS. 12 A- 12 B and FIGS. 13 A- 13 B The internal components of an applicator wherein the actuating member's upper external surface is flush with the uppermost (proximal with respect to the skin contacting surface of the housing) surface of housing can vary, and two embodiments are shown in FIGS. 12 A- 12 B and FIGS. 13 A- 13 B , wherein like elements with respect to FIGS. 11 A- 11 B are given like numerical identifiers despite FIGS. 12 A- 12 B and FIGS. 13 A- 13 B being different embodiments.
- applicator 400 is shown in a side cross-sectional view.
- First member 404 of housing 402 has an upper rim 420 that defines an uppermost plane of the applicator, the upper plane denoted by the dashed line 414 .
- Actuating member 410 is movably positioned in the housing, movable between first and second positions, where in its first position the upper surface of the actuating member, denoted by the plane indicated by dashed line 412 , is co-planar with the upper plane of the applicator or is slightly lower than the upper plane of the applicator, as seen in FIG. 12 A .
- the actuating member travels to its second position, for deployment into the skin of a user of a microneedle array (not shown) positioned on a holding member 424 engaged with the actuating member.
- the upper surface of the actuating member approaches, contacts, or travels beyond, a plane defined by an upper rim of the second housing member 406 , the plane denoted by dashed line 416 .
- actuating member 410 travels from its first to second positions along a plurality of guide fins, such as fins 426 , 428 .
- a groove for each guide fin such as groove 430 , is disposed in actuating member. Grooves or slots are similarly provided in the first and second members of the housing, to secure each guide fin in the applicator.
- the plurality of guide fins guide the plunger of the actuating member relative to the housing to maintain alignment during activation of the device.
- Each guide fin is dimensioned with sufficient thickness to avoid sharp edges, and the edges can be curved with a radius of curvature to ensure no sharp edging. It is also desirable that each guide fin have a horizontal axis of symmetry that allows for its insertion into the housing in either direction.
- FIGS. 13 A- 13 B are cross-sectional side views of another embodiment of the applicator of FIGS. 11 A- 11 B , wherein FIG. 13 A shows the applicator prior to activation and FIG. 13 B shows the applicator after its activation.
- the applicator prior to activation has an actuating member 410 that is recessed within the housing, as evident from the fact that the upper surface of the actuating member is below or under the upper rim of the first housing member 404 , as illustrated by the respective dashed lines 412 (corresponding to the plane defined by the upper surface of the actuating member) and 414 (corresponding to the plane defined by the plane defined by upper rim of the first housing member).
- the actuating member 410 that is recessed within the housing, as evident from the fact that the upper surface of the actuating member is below or under the upper rim of the first housing member 404 , as illustrated by the respective dashed lines 412 (corresponding to the plane defined by the upper surface of the actuating member) and 414 (
- activation of the actuating member by application of a force moves the actuating member to its second position, wherein the upper surface of the actuating member is closer (relative to the upper surface of the actuating member in its first position) to the upper rim 407 of the second housing member 406 , denoted by dashed line 416 .
- the actuating member travels from its first to second positions along a plurality of guide posts, such as posts 432 , 434 .
- the guide posts extend from the first member of the housing to the second member of the housing, and are affixed to the each member.
- the outer circumference of the actuating member contacts each of the guide posts, which serve to guide the actuating member relative to the housing during movement of the actuating member.
- FIGS. 12 A- 12 B and 13 A- 13 B also illustrate the energy storage element 436 positioned with the applicator.
- the energy storage element moves from a first position to a second position upon application of a force by the actuating member. Movement from its first to its second position occurs only upon application of a sufficient force, and results in an inversion of the element.
- the element is stable in both its first and second positions in that it does not of its own accord move between the positions, but requires application of force to move from its first to its second position, and from its second position to its first position.
- the force required to move the element from its second to its first position is less than the force required to move the element from its first to its second position.
- the element Absent application of force, the element cannot return to its first position subsequent to actuation of the device.
- the energy storage element Prior to activation of the applicator, the energy storage element contacts the second housing member that is in contact with the skin, and after activation, the energy storage element is in contact with the first member of the housing (also referred to as an outer cover).
- Activation of the actuation member releases energy stored in the energy storage element, the release energy acting on the microprojection holding member in contact with the actuating member.
- a method for administering an active agent to a subject comprises providing a microprojection array in conjunction with any one of the applicators described herein, the microprojection array comprising an active agent.
- the agent is delivered transdermally by actuation of the applicator, to deploy the microprojection array into contact with the skin, or more generally a membrane or body surface, of a subject.
- the active agent to be administered can be one or more of any of the active agents known in the art, and include the broad classes of compounds such as, by way of illustration and not limitation: analeptic agents; analgesic agents; antiarthritic agents; anticancer agents, including antineoplastic drugs; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics, antifungal agents, antiviral agents and bacteriostatic and bactericidal compounds; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; anxiolytics; appetite suppressants; attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular preparations including calcium channel blockers, antiang
- the agent is a vaccine.
- Example 1 details administration of human parathyroid hormone to porcine skin in vitro.
- Examples 2-4 detail administration of human parathyroid hormone to human subjects. Additional details of administration of human parathyroid hormone to human subjects using a microprojection array, including detailed pharmacokinetic analysis, are given in provisional application No. 61/331,226, filed May 4, 2010; the entire contents of this co-filed application are incorporated by reference herein.
- peptides and proteins which may be used with microneedle arrays are oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone, follicle stimulating hormone, luliberin or luteinizing hormone releasing hormone (LHRH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, tumor necrosis factor, colony stimulating factors, motilin, bombesin, dinorphin, neurotensin, cerulein, bradykinin, urokinase
- Peptidyl drugs also include synthetic analogs of LHRH, e.g., buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide (leuprorelin), lutrelin, nafarelin, tryptorelin, and pharmacologically active salts thereof.
- Administration of oligonucleotides are also contemplated, and include DNA and RNA, other naturally occurring oligonucleotides, unnatural oligonucleotides, and any combinations and/or fragments thereof.
- Therapeutic antibodies include Orthoclone OKT3 (muromonab CD3), ReoPro (abciximab), Rituxan (rituximab), Zenapax (daclizumab), Remicade (infliximab), Simulect (basiliximab), Synagis (palivizumab), Herceptin (trastuzumab), Mylotarg (gemtuzumab ozogamicin), CroFab, DigiFab, Campath (alemtuzumab), and Zevalin (ibritumomab tiuxetan).
- the applicators B1, B2 and B3 differed in the precise characteristics of the slotted spring energy-storing element (dimensions and material).
- Applicator B1 was 0.012 inches thick stainless steel
- Applicator B2 was 0.0155 inches thick and made of 17-7 stainless steel
- Applicator B3 was 0.0155 inches thick and made of 301 stainless steel.
- the B1 slotted springs had somewhat longer indentations from the outside in comparison to the B2 and B3 slotted springs.
- Microprojection arrays were fabricated from Dextran-70 and containing hPTH(1-34), as described in U.S. Publication No. 2008-0269685.
- the sequence of hPTH(1-34) used was:
- microneedles were 4-sided pyramids with spacing 200 microneedle height 250 and array diameter 11 mm, with 2742 microneedles per array.
- SPE Skin penetration efficiency
- a microprojection array containing a therapeutically effective amount of hPTH(1-34) (32 ⁇ grams) was prepared for use in a Phase I clinical study as follows.
- the microprotrusions of the array can be characterized generally as comprising a DIT (drug-in-tip) layer and a “backing” layer.
- the DIT layer includes hPTH(1-34) in a water-soluble matrix.
- the sequence of hPTH(1-34) used is as follows:
- the tip of the microprojections is also referred to herein as the layer at the bottom-most portion of the tips or microprotrusions (i.e., proximal to the skin when placed upon the skin), also referred to herein as the “end portion” that is distal to the base of the array).
- the “backing” layer as referred to in certain of these examples, encompasses both the upper portion of the microprotrusions proximal to the base of the array as well as the base itself, where the base is the portion of the array that supports the tips.
- the backing layer comprises a biocompatible, non-water soluble matrix.
- the material in the upper portion of the microprotrusions is the same as the base material itself, so that the non-water soluble matrix formulation is applied as a single layer to fill the mold atop the DIT layer.
- the DIT layer of the microstructure array dissolves into the skin and contains the components provided in Table 2-1.
- Acetate was the counter-ion in the hPTH(1-34) drug substance.
- the backing portion or layer of the array was composed of poly(DL-lactide-co-glycolide), 75:25, ester terminated (Tradename: LACTEL®).
- the ingredients forming the tip portion of the formulation i.e., the DIT formulation
- the water insoluble, biocompatible polymer, poly(DL-lactide-co-glycolide), 75 : 25 was dissolved in acetonitrile to provide the backing formulation which was then coated on top of the DIT layer in the silicone mold, and then dried.
- the solvent was removed from the backing (upper portion proximal to the base, and base) during processing and was limited to a level below the amounts recommended in ICH guidelines.
- Tds Transdermal Delivery Device
- hPTH(1-34) Human Parathyroid Hormone
- the final transdermal/microneedle delivery system product (sometimes abbreviated herein “TDS”) was assembled and contained the microprojection array described above in Example 2.
- the product was designed to deliver a systemic dose of hPTH (1-34) across the stratum corneum barrier layer of the skin using an array of microstructures.
- the final TDS product was formed by the integration of two components, a plunger-array assembly containing drug product and an applicator assembly, where these two items were packaged separately and integrated at the clinical site (See Example 4 below for clinical data).
- the microprojection array contained in the plunger-array assembly possesses an 11 millimeter diameter of approximately 2700 microstructures arranged in a hexagonal pattern.
- the plunger-array assembly consists of the microprojection array mounted to an array support member, in this case, as plastic plunger with an adhesive laminate.
- the plunger-array assembly was packaged inside a protective container and pouched in a dry nitrogen environment.
- the applicator assembly includes a plastic shell or housing with skin contact adhesive and a release liner, an energy storage member (in this case, a metal spring) to provide the energy needed to accelerate the plunger-array assembly, and elements to hold these items together until assembly at the clinic with the plunger-array assembly.
- This unit is packaged inside a protective container and pouched.
- the final assembled drug product consists of the plunger-array assembly which is inserted into the applicator assembly.
- the TDS is activated by compressing the spring and then twisting the plunger to lock and hold the compressed spring in place until use.
- the spring delivers the stored energy to the plunger causing it to accelerate and contact the skin.
- the microstructures penetrate past the stratum corneum, and the hPTH dissolves into the skin rapidly.
- the device is removed and discarded.
- the applicator assembly and plunger-array assembly as well as the final assembled TDS product correspond to those shown in FIGS. 4 A- 4 B .
- the plasma sampling schedule was as follows: pre-treatment, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 120, 180, 240, 300, 360 minutes, and 24 hours post-treatment. Vital signs were monitored pre-treatment, and at 15 and 30 minutes, and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-treatment. Adverse advents were monitored throughout the study.
- hPTH with the MicroCor device demonstrated good skin tolerability. Skin effects were transient and well-tolerated, with mild to moderate erythema observed.
- the MicroCor® delivery system exhibits rapid pharmacokinetic properties such as a shorter T max , a higher C max , and a shorter elimination half life, T 1/2 , as compared to a subcutaneous injection of the agent.
- Absorption of hPTH (1-34) occurred more rapidly with the MicroCor® delivery system relative to the Forteo® product, as illustrated by the higher dose-normalized C max value and the faster T max values for both MicroCor® treatments.
- the half-life based upon administration via the MicroCor® device as also shorter than with Forteo®.
- application using the MicroCor® device was more effective in achieving the desired pulsatile delivery profile of hPTH(1-34) (i.e., rapid on set and rapid offset after reaching C max ).
- the MicroCor®-based delivery results in faster elimination of drug. Based upon a plot of plasma concentration (normalized) versus time, it can be seen that the time to reach 50% of C max for the MicroCor®-based treatments was approximately 20 minutes for both the 32 and 64 microgram treatments (i.e., based upon the time to reach a normalized plasma concentration of 0.5). In contrast, the time to reach 50% of C max for the Forteo®-based treatment was approximately 1.5 hours (90 minutes), based upon time post-administration.
- the time to reach 50% of C max for the MicroCor®-based treatments was approximately 4.5 times less than that observed for subcutaneously injected PTH)(Forte® indicating notably faster elimination of drug when administered transdermally from a microneedly array as in the MicroCor® system.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
Abstract
An applicator for a microprojection array is described. In one embodiment, the applicator comprises an energy-storing element. Application of force causes the compressed energy-storing element to extend or transition from first and second configurations, releasing stored energy to deploy a holding member in the application which is configured to hold an array of microprojections. In another embodiment, the applicator comprises an energy storing element with two stable configurations, a first stable configuration and second stable configuration. Application of force causes the energy-storing element to transition from the higher energy first stable configuration to the lower energy second stable configuration, releasing the difference in energies of the two states to deploy a holding member in the application which is configured to hold an array of microprojections.
Description
- This application is a continuation of U.S. application Ser. No. 17/185,746, filed Feb. 25, 2021, which is a continuation of U.S. application Ser. No. 15/633,583, filed Jun. 26, 2017, now issued as U.S. Pat. No. 10,946,180 on Mar. 16, 2021, which is a continuation of U.S. application Ser. No. 13/100,924, filed May 4, 2011, now issued as U.S. Pat. No. 9,687,640 on Jun. 27, 2017, which claims the benefit of and priority to U.S. Provisional Application No. 61/331,175, filed May 4, 2010, each of which is incorporated herein by reference in their entireties.
- The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 10, 2023, is named CPS-8127C3_SL.txt and is 1,888 bytes in size.
- The subject matter described herein relates generally to drug delivery using microneedles or other microprojections, and more specifically to applicators for applying an array of microprojections to the stratum corneum.
- Arrays of microneedles were proposed as a way of administering drugs through the skin in the 1970s, for example in expired U.S. Pat. No. 3,964,482. Microneedle arrays can facilitate the passage of drugs through human skin and other biological membranes in circumstances where ordinary transdermal administration is inadequate. Microneedle arrays can also be used to sample fluids found in the vicinity of a biological membrane such as interstitial fluid, which is then tested for the presence of biomarkers.
- In recent years it has become more feasible to manufacture microneedle arrays in a way that makes their widespread use financially feasible. U.S. Pat. No. 6,451,240 discloses some methods of manufacturing microneedle arrays. If the arrays are sufficiently inexpensive, for example, they may be marketed as disposable devices. A disposable device may be preferable to a reusable one in order to avoid the question of the integrity of the device being compromised by previous use and to avoid the potential need of resterilizing the device after each use.
- In addition to cost, integrity and sterility, a further issue with microneedle arrays is bioavailability of the active agent. An intravenous injection delivers a precise quantity of an active agent to the circulation. A subcutaneous or intramuscular injection delivers a precise quantity of an active agent into the tissue, but the quantity of active agent delivered to the circulation and the rate at which active ingredient is delivered are affected by the type of surrounding tissue, circulation, and possibly other factors. When a drug is delivered orally, the resulting blood levels may exhibit substantial variation among patients due to metabolism and other factors, but minimal therapeutic levels can be assured for most patients, for example, because the rate of metabolism has an upper limit and because there is long experience with the absorption of many drugs from oral formulations. When a drug is delivered to unmodified skin by a conventional transdermal patch, the bypassing of the hepatic circulation may lessen the effect of liver metabolism on bioavailability. On the other hand, with a conventional transdermal patch, differences in skin permeability are an additional factor leading to differences in bioavailability.
- Microneedles manipulate the permeability of the skin with respect to the active agent. Variability in the permeability enhancement created by different applications of the microneedles will result in variations in the rate of transfer through the skin, the amount transferred through the skin and the bioavailability. Variability of skin permeability enhancement on the application of a microneedle array can result from application on different patients. Particular concern exists, of course, if the enhancement is small in particular patient populations so that the administration of the drug will not produce a therapeutically effective dosing (e.g., adequate blood levels) in those populations. Concern may arise also if the enhancement is sometimes undesirably small in a patient, even if at other times the enhancement is as expected in that patient, depending on details of how and where the microneedle array is applied.
- A typical microneedle array comprises microneedles projecting from a base of a particular thickness, which may be of any shape, for example square, rectangular, triangular, or circular. The microneedles themselves may have a variety of shapes. While an array could be pressed by hand into skin, it has also been proposed to use a variety of devices to hold the microneedle array as it is being applied or to facilitate in one way or another the process of microneedle array application to the skin or other biological membrane. Such devices may broadly be referred to as “applicators.” Applicators may for example reduce the variations in force, velocity, and skin tension that occur when a microneedle array is pressed by hand into the skin. Variations in force, velocity and skin tension can result in variations in permeability enhancement.
- In some applications of microneedle arrays, they may be applied to the skin or other biological membrane in order to form microchannels and then are more or less immediately withdrawn. In other applications the microneedle array may be held in place for a longer period of time. The design of the applicator may naturally be influenced by how long the microneedles are expected to stay in place.
- Applicators for microneedles comprising components which have two stable states have been described in U.S. Published Patent Application No. 2008/0183144. The existence of two stable states is a feature generally desired in an applicator because the energy difference between the two stable states can allow each use of the applicator to employ a fixed amount of energy in order to cause penetration, improving reproducibility. However, a limitation of this earlier approach is that the energy delivered to the microstructure array is both limited and variable. The earlier approach was dependent on the input of the user for both energy and velocity, and variation in application technique had a significant effect on the ability of the device to enhance the permeability of the skin.
- In some other prior art applicator designs, the energy storage element, such as a spring or elastic element, may exert forces on one or more components of the applicators, leading to dimensional distortion and creep over an extended period of time. These effects are undesirable as they lead to variations in the applicator geometry and a loss in the stored elastic energy over time. Therefore, there is a need for an applicator which has energy storage elements that do not exert forces on one or more components of the applicator.
- In the use of microneedle arrays, particularly when the arrays are kept in place for a prolonged period of time, devices to transport the drug substance to the skin may be employed. A very simple such device may, for example, comprise a reservoir for liquid or solid drug substance which is kept in contact with the base, with the liquid drug substance flowing through small apertures in the base or by diffusion when solid drug substance is used. Another device suitable for delivering the drug substance to skin is described in U.S. Published Patent Application No. 2005/0094526. Rotary applicators have been disclosed in U.S. Published Patent Application No. 2004/0087992. There is some disclosure relating to applicators, for example, in U.S. Pat. Nos. 6,537,242, 6,743,211 and 7,087,035.
- There is a need in the art for applicators and related devices suitable for use with microneedle arrays, for example, in order to assist in making the process of drug delivery more user friendly and uniform across patients and for different applications to the same patient.
- In one aspect, an applicator for a microprojection array is provided. The applicator comprises an energy-storing element which has a first stable configuration and second stable configuration, wherein application of force can cause the energy-storing element to transition from the first stable configuration to the second stable configuration, and wherein the force necessary for the energy storing element to transition from the first stable configuration to the second stable configuration is lower than the force necessary for the element to transition from the second stable configuration to the first stable configuration. The applicator also comprises an actuating member that can convey external force to the energy-storing element, a microprojection-holding member connected to the actuating member and which is acted on by the energy-storing element when it transitions from the first stable configuration to the second stable configuration, an outer cover with an opening into which the actuating member fits slidably, and a skin-contacting member comprising a portion which can lie flat against skin, wherein the skin-contacting member fits the outer cover and contacts the energy-storing element when it is in its first configuration.
- In one embodiment, the energy-storing element has an axis of symmetry and n-fold rotational symmetry for some integer n. In another embodiment, application of force to the energy-storing element in a direction of its axis of symmetry causes it to transition from the first stable configuration to the second stable configuration.
- In another embodiment, an applicator for a microprojection array comprises a housing having a surface with an elongated opening having platforms on opposite sides of the opening. An actuation member comprising a surface upon which a microprojection array can be attached, a generally washer-shaped surface on which an energy-storage member can be placed, and a surface capable of mating with the platforms on the opening of the housing and capable of fitting through the opening is included. An energy-storage member is situated between the actuation member and the housing, and a skin-contacting area which is generally washer-shaped is connected to the housing. In one embodiment, when the actuation member is mated with the platforms on the opening, the energy-storage member is compressed, and when the actuation member is moved within the opening so that it no longer mates with the platforms, the energy-storage member is free to expand and in so doing moves the actuation member.
- In one embodiment, the energy-storage member is in the form of a wave spring. In other embodiments, the energy storage member has an n-fold rotational axis of symmetry of between about 3-22, more preferably 3-18 or 3-9, and still more preferably between 3-6.
- In another embodiment, the actuator member moves within the outer cover between a first position and a second position, wherein in its first position the actuator member extends outwardly from and beyond an upper surface of the outer cover.
- In another embodiment, the actuator member moves within the outer cover between a first position and a second position, wherein in its first position the actuator member is recessed within the outer cover.
- In yet another embodiment, the microprojection array is attached to the microprojection-holding member, the microprojection array comprises a base, and the level of the microprojection array's base is below a skin-contacting surface of the skin-contacting member following actuation of the actuating member.
- In still another embodiment, the level of the microprojection array's base below the skin-contacting surface of the skin-contacting member is between about 0.001 inches to about 0.200 inches, more preferably between about 0.001 inches to about 0.125 inches, still more preferably from about 0.030 inches to about 0.090 inches.
- In another embodiment, the energy-storing element is in mechanical coupling relationship with the microprojection-holding member when the energy-storing element is in its first stable configuration.
- In another aspect, an applicator for a microprojection array is provided. The applicator comprises (a) a housing having a surface with an elongated opening having platforms on opposite sides of the opening; (b) an actuation member comprising a surface upon which a microprojection array can be attached, a generally washer-shaped surface on which an energy-storage member can be placed, and a surface capable of mating with the platforms on the opening of the housing and capable of fitting through the opening; (c) an energy-storage member situated between the actuation member and the housing; and (d) a skin-contacting area which is generally washer-shaped connected to the housing. When the actuation member is mated with the platforms on the opening, the energy-storage member has a first force of stored energy, and when the actuation member is moved within the opening so that it no longer mates with the platforms, the energy-storage member releases its stored energy and in so doing moves the actuation member.
- In one embodiment, the energy-storage member when mated with the platforms on the opening has a first force of stored energy by virtue of its being compressed.
- In yet another aspect, an applicator is provided. The applicator comprises (a) a housing having a first member with a central opening and a second member having a skin contacting surface; (b) an actuation member disposed in the central opening and comprising a surface upon which a microprojection array can be attached and a groove extending circumferentially; and (c) an energy-storage member having an inner edge and an outer edge, and situated within the housing initially in a first stable configuration such that the inner edge is disposed in the groove and its outer edge is in contact with the second member. Application of force to the actuation member moves the energy-storage member from its first stable configuration to a second stable configuration wherein the outer edge is no longer in contact with the second member.
- In one embodiment, the outer edge of the energy storage member in its second stable configuration is in contact with the first member.
- In another embodiment, a microprojection array holder engages the actuation member, the engagement of the actuation member and the microprojection array holder defining the groove.
- In still another embodiment, the energy-storage member has an axis of symmetry and n-fold rotational symmetry for some integer n, wherein application of force in a direction of the axis of symmetry causes the energy-storing element to transition from the first stable configuration to the second stable configuration, and wherein the force necessary for the energy storing element to transition from the first stable configuration to the second stable configuration is lower than the force necessary for the element to transition from the second stable configuration to the first stable configuration.
- In yet another embodiment, the energy-storing element is of generally frustoconical shape with slots from the top of the frustum, from the bottom of the frustum, or from both.
- In another aspect, any of the applicator embodiments described herein further comprises a safety mechanism to prevent movement of the actuation member in a direction that deploys the microprojection array.
- In one embodiment, the safety mechanism comprises a protective cap over the applicator housing. In another embodiment, the safety mechanism comprises a pin movably inserted into the actuation member on an applicator.
- In another aspect, a device comprising an applicator in accord with any of the aspects and embodiments described herein and a microprojection array comprising an active agent is provided.
- In another aspect, a method for applying a microprojection array to a biological barrier is provided. The method comprises providing an applicator as described herein, the applicator including or capable of including a microprojection array. The applicator is contacted with the biological barrier, and an actuating member on the applicator is activated, to initiate movement of the energy-storage member from its first stable configuration to its second stable configuration. Movement of the energy-storage member induces movement of the microprojection array, directly or indirectly, causing it to forcibly contact the biological barrier. In embodiments where the microprojection array comprises a therapeutic or prophylactic agent, the method achieves administration of the agent to a subject.
- Additional embodiments of the present method, microprojection array, kit, and the like will be apparent from the following description, drawings, examples, and claims. As can be appreciated from the foregoing and following description, each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present disclosure provided that the features included in such a combination are not mutually inconsistent. In addition, any feature or combination of features may be specifically excluded from any embodiment of the present invention. Additional aspects and advantages of the present invention are set forth in the following description and claims, particularly when considered in conjunction with the accompanying examples and drawings.
-
FIGS. 1A-1C are views of an applicator as described herein, the applicator shown in perspective views (FIG. 1A ), a sectional view (FIG. 1B ) and an exploded view (FIG. 1C ). -
FIGS. 1D-1E show the applicator ofFIGS. 1A-1C in perspective view (FIG. 1D ) and in a cross-sectional view (FIG. 1E ) after actuation of its actuating member. -
FIGS. 1F-1T are perspective views of embodiments of energy-storage elements for use in an applicator as described herein. -
FIGS. 1U-1V illustrate movement of an energy-storage element between its first stable configuration and its second stable configuration. -
FIG. 2A depicts schematically, with certain dimensions exaggerated for clarity, an applicator. -
FIG. 2B depicts schematically, with certain dimensions exaggerated for clarity, one quarter of the push member of the applicator ofFIG. 2A . -
FIGS. 3A-3B depict schematically another embodiment of an applicator, where inFIG. 3A a schematic cross-section of one half of the applicator is shown, and inFIG. 3B a perspective view of a particular component is shown. -
FIG. 4A shows an exploded view of another embodiment of an applicator.FIG. 4B shows a perspective view of the same applicator. -
FIG. 5 depicts an alternative outer member for the applicator ofFIGS. 4A-4B . -
FIGS. 6A-6B illustrate a cantilevered pin safety mechanism to prevent unintentional deployment of an activator. -
FIGS. 7A-7B illustrate another embodiment of a safety mechanism to prevent unintentional deployment of an activator. -
FIGS. 8A-8B illustrate an example of tab safety mechanisms to avoid accidental actuation of an actuation member in an applicator. -
FIGS. 9A-9C illustrate another embodiment of a safety mechanism, where a protective cap is shown in a closed position (FIG. 9A ) and in an open position (FIG. 9B ), and disposed in place on an applicator (FIG. 9C ). -
FIGS. 10A-10B illustrate another embodiment of a cap type safety mechanism. -
FIGS. 11A-11B are perspective views of an applicator according to yet another embodiment, whereinFIG. 11A depicts the applicator in a configuration prior to deployment or actuation by a user, andFIG. 11B depicts the same applicator after deployment or actuation by a user. -
FIGS. 12A-12B are cross-sectional side views of a first embodiment of internal components of an applicator according to the applicator ofFIGS. 11A-11B , whereinFIG. 12A depicts the applicator in a configuration prior to deployment or actuation by a user, andFIG. 12B depicts the same applicator after deployment or actuation by a user. -
FIGS. 13A-13B are cross-sectional side views of a second embodiment of internal components of an applicator according to the applicator ofFIGS. 11A-11B , whereinFIG. 13A depicts the applicator in a configuration prior to deployment or actuation by a user, andFIG. 13B depicts the same applicator after deployment or actuation by a user. - Before describing the present subject matter in detail, it is to be understood that this invention is not limited to specific materials or device structures, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
- As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include both singular and plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an active ingredient” includes a plurality of active ingredients as well as a single active ingredient, reference to “a temperature” includes a plurality of temperatures as well as single temperature, and the like.
- For information regarding words which have multiple meanings, reference is made to The Oxford English Dictionary (2d ed. 1989) and the McGraw-Hill Dictionary of Scientific and Technical Terms (6th ed. 2002), which are incorporated by reference herein. The inclusion of these references is not intended to imply that every definition in them is necessarily applicable here, as persons of skill in the art would often see that a particular definition is not in fact applicable in the present context.
- In this application reference is often made for convenience to “skin” as the biological membrane which the microneedles penetrate. It will be understood by persons of skill in the art that in most or all instances the same inventive principles apply to the use of microneedles to penetrate other biological membranes such as, for example, those which line the interior of the mouth or biological membranes which are exposed during surgery.
- In this application reference is also made to “microneedles” as the type of microprotrusion or microprojection which is being employed. It will be understood by persons of skill in the art that in many cases the same inventive principles apply to the use of other microprotrusions or microprojections to penetrate skin or other biological membranes. Other microprotrusions or microprojections may include, for example, microblades as described in U.S. Pat. No. 6,219,574 and Canadian patent application no. 2,226,718, and edged microneedles as described in U.S. Pat. No. 6,652,478.
- In discussing the applicators of this invention, the term “downward” is sometimes used to describe the direction in which microprotrusions are pressed into skin, and “upward” to describe the opposite direction. However, those of skill in the art will understand that the applicators can be used where the microprotrusions are pressed into skin at an angle to the direction of the earth's gravity, or even in a direction contrary to that of the earth's gravity. In many applicators of the invention, the energy for pressing the microprotrusions is provided primarily by an energy-storage member and so efficiency is not much affected by the orientation of the skin relative to the earth's gravity.
- The sizes of the microneedles and other microprotrusions for use with the applicators described herein will be a function of the manufacturing technology and of the precise intended application (e.g., the active agent to be delivered, whether it is contained in the microprojections, etc.). In general, however, microneedles and other microprotrusions used in practice may be expected to have a length of about 20 to about 1000 microns, more preferably from about 50 to about 750 microns and most preferably from about 100 to about 500 microns. Often it will be desired that the microprotrusions will be long enough to penetrate through the stratum corneum layer of skin at some suitable point of application on the human body, for example the thigh, hip, arm, or torso.
- The term “microneedle array” for purposes herein is intended to denote a two-dimensional or a three-dimensional arrangement of microneedles. The arrangement may be regular according to a repeating geometric pattern or it may be irregular. Similarly, “microprojection array” denotes a two-dimensional or three-dimensional arrangement of microprojections.
- In a first aspect, an applicator for microprojection arrays is provided in which the velocity at the time of microprojection array contact with skin is controlled within a predetermined range. The applicator operates when an actuating element is pressed with a force which is above a threshold. The velocity of contact is substantially independent of the precise force employed to press the actuating element. The applicator comprises an energy-storing element.
- In a further aspect, a method for inserting microprojections in an array of microprojections into skin or another biological barrier is provided. The method comprises placing an applicator in contact with the barrier into which the array is to be inserted and operating an actuating element which forms part of the applicator with a force which lies above a predetermined threshold. The velocity of the microprojection array and the energy per microstructure at the time of contact with skin need to be above a threshold and may be controlled within a predetermined range.
- Applicators contemplated herein will commonly have two states or configurations. In the first state or configuration, the applicator has the microprojection array recessed. This is expected to be the state of the applicator following manufacturing and during shipping and storage. In the second state or configuration, which is arrived at by pressing or otherwise operating the actuating element, the microprojection array projects modestly outward from the applicator.
- The velocity of the microprojection array at the time of contact with skin may be adjusted, for example, by varying the amount of stored energy in the energy-storing element. This is done, for example, by controlling the energy-storing element's geometric design and the properties of the material(s) out of which the energy-storing element is made. The energy-storing element may have a compressed form in which the degree of compression (e.g., in one spatial direction) controls the amount of energy stored.
- When the energy storing element is stored in compressed form, a variety of mechanisms external to the element, but forming part of the applicator, may be employed to release the compression and allow the element to uncompress and therefore release some or all of its energy.
- Alternatively, the energy-storing element may be bistable in that it has two stable states in which energy is stored. The two states may have different energies. The amount of stored energy may be, for example, in the range of about 0.1 J to about 10 J, or in the range of about 0.25 J to about 1 J. The energy storage element having two bi-stable states is highly advantageous because in its higher energy state, the energy storage element does not exert any significant forces on the applicator components, thereby alleviating the problems with dimensional distortion and creep over time. Reducing the dimensional distortion and creep lead to maintaining the same stored elastic energy for an extended period of time. Maintaining the same stored elastic energy over a period of time is important for having an extended shelf life of at least preferably 6 months, more preferably 12 months, and most preferably 24 months.
- The velocity of the microprojection array at the time of contact with the skin may lie, for example, within the range of 0.1 m/s to 20 m/s, or within the range of 0.5 m/s to 10 m/s. In general, the stored energy may be employed in moving the microprojection array into contact with the skin as well as in overcoming any forces (e.g., from other components of the applicator) acting on the microprojection array. In addition, the stored energy may be employed in moving other components which, in accordance with the design of the applicator, must also move as the microprojection array moves towards the skin.
- The velocity of the microprojection array is preferably reproducible. For example, the standard deviation of the velocity in a number of applications carried out with different applicators of the same design or by different persons using the same applicator may be less than about 10% of the average velocity, less than about 5%, or less than about 1%.
- It may be desired that the applicator comprise one or more components which have rotational symmetry about an axis perpendicular to the microprojection array. For example, the applicator may comprise components which have n-fold rotational symmetry (symmetry under rotations of 360/n degrees), for some integer n>1, for example n=2, 3, 4, 5, or 6. To give an example, the clip depicted in
FIG. 3B , a component of an applicator described herein, has 3-fold rotational symmetry. - It may be desirable that the energy-storing element be in mechanical coupling relationship with the microprojection array or a member holding the array at all times. An alternative design, however, would allow the energy-storing element not to be coupled to the microprojection array during the stored state of the applicator but only to come into contact with the array or a member holding the array during the process of actuation. Such contact may occur at a nonzero velocity, although it is desirable that this nonzero velocity be low, for example below about 0.1 cm/s, or below about 0.25 cm/s or below about 1 cm/s.
- Following contact of the microneedle array with skin or another barrier, there may be a modest bounce of the array against the skin given that skin has elastic properties. The microneedle array may then settle, pressed by the applicator, into the skin at a level which is modestly below the original level of the skin. The force with which the microprojection array is pressed into the skin may be, for example, between about 0.1 and about 10 N/cm2. The level of the microprojection array's base below the skin is about 0.001 inches (0.00254 cm) or greater, and in other embodiments is between about 1/16 inch (0.0625 inches or 0.159 cm) and about 3/16 inch (0.188 inches or 0.476 cm), or between about 1/16 inch (0.0625 inches or 0.159 cm) to about ⅛ inch (0.125 inches or 0.318 cm).
- In a common arrangement where a compressed energy-storage device is employed, the applicator has a primary member, which is contacted with skin when the applicator is to be used. The microprojection array is attached to a retaining member which holds the energy storage device in compression. The retaining member is held in place by a flexible mechanism. The actuation mechanism causes the flexible mechanism to be displaced or elastically deformed in such a way that the retaining member ceases to be restrained. The energy-storage device is then free to expand or to move between first and second configurations, moving the retaining member, and the microprojection array is then displaced towards the skin.
- Turning now to the drawings,
FIGS. 1A-1C depict several views one possible arrangement of anapplicator 10. The applicator comprises askin contacting element 12 which has anopening 14 in its center, and, in this embodiment, has complete rotational symmetry. Skin-contactingelement 12 mates with anapplicator housing 16 which, in this embodiment, also has complete rotational symmetry and is manufactured from a rigid material (e.g., a polymeric, filled polymeric, composite, or metal material) which preferably does not visibly flex during operation of the device). It will be appreciated that the housing can also be semi rigid, semi-flexible, or flexible, if desired.Housing 16 has anopening 18 at the top, through which an actuatingmember 20 slidingly fits. As seen best inFIG. 1B , connected to abottom surface 22 of actuatingmember 20 is aholder 24 which holds a microprojection array (which is not shown inFIGS. 1A-1C ). Whenbottom surface 22 and the upper surface ofholder 24 are in contact, agroove 26 is defined which again has complete rotational symmetry. A bistable energy-storage member 28 having an approximately frustoconical form has aninner edge 30 positioned withingroove 26. The energy-storage member of this embodiment is referred to herein as a “slotted spring”, described in further detail hereinbelow. -
FIGS. 1D-1E illustrate the applicator after actuation of actuatingmember 20.Housing 16 and its lower portion withskin contacting element 12 are shown inFIG. 1D , where actuatingmember 20 is not visible because it has been depressed and is fully retained within the housing. Extending slightly beyond theskin contacting element 12 is the bottom surface of the actuating member on which an array of microprojections is held.FIG. 1E is a cross-sectional view taken along line A-A inFIG. 1D , where the actuating member contained within the housing is visible. Also visible is the configuration of the slottedspring member 28 where itsinner edge 30 is in a second position relative to it is position prior to actuation, as depicted inFIG. 1B . Specifically,inner edge 30 of the energy-storage member is at a horizontal plane that approaches or approximates the horizontal plane of the edge of the slotted spring prior to use. This transition and inversion of the spring element are described in more detail below. - The materials from which the applicator components are manufactured can be selected from a wide variety known to a skilled artisan. For example, a filled polymer material is suitable for manufacture of the outer cover, the actuating member and/or the microprojection holding member. A skilled artisan will understand the various material properties to be considered when selecting a suitable material for each component part.
-
FIGS. 1F-1G are perspective views of two different embodiments of energy-storage members for use in an applicator as described herein, such as that depicted inFIGS. 1A-1E . Energy-storage member 40 ofFIG. 1F is substantially in the shape of a washer, and more specifically approximately a frustoconical shape. Inner rim 42 of the member andouter rim 44 of the member define adisc region 46. Upper slots, such asupper slots lower slots outer rim 44. The upper and lower slots are offset from one another, so that a lower slot is positioned between adjacent upper slots, and vice versa. The slots serve to reduce strain of the material during its movement between its first and second stable configurations, as will be described. -
FIG. 1G illustrates an alternative embodiment of an energy-storage member 60. Energy-storage member 60 ofFIG. 1G is substantially in the shape of a washer, and more specifically a frustoconical shape. Inner rim 62 of the member andouter rim 64 of the member define adisc region 66. A plurality of slots, such asslots - The energy-storage members of the present applicator are movable between first and second stable configurations. In the first stable configuration, the inner edge (or rim) of the energy-storage member lies in a first
horizontal plane 72 and the outer edge (or rim) of the energy-storage member lies in a secondhorizontal plane 74 that is lower than the first horizontal plane, as depicted inFIGS. 1U-1V . Application of force to the energy-storage member causes movement to a second stable configuration, where the inner edge of the energy-storage member approaches the second horizontal plane and the outer edge of the energy-storage member approaches the first horizontal plane. In a sense, the relative positions of the inner rim and outer rim invert as the member transitions from a first to a second stable configuration, and back. In one embodiment, the force for movement from the first stable configuration to the second stable configuration is less that the force needed to move the member from the second stable configuration to the first stable configuration. In one embodiment, a force of at least 10% greater, preferably 20% greater, still more preferably 30% greater is needed to transition the member from its second stable configuration to its first stable configuration. - In a preferred embodiment, the energy-storage member as an axis of symmetry with an n-fold rotational symmetry for n, where n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In a preferred embodiment, n is between 3-18, preferably between 3-12, still more preferably between 3-9. By way of example, the slotted spring embodiment of
FIG. 1G has an axis of symmetry with a 9-fold rotational symmetry. The energy-storage member is stable in both its first and second configurations, wherein stable intends that the member does not transition between first and second configurations except upon application of external force. As noted above, in a preferred embodiment, the force to move from a second configuration to a first configuration is different, e.g., greater, than the force needed to move from a first configuration to a second configuration. - A skilled artisan will appreciate the wide variety of energy-storage members that would be suitable for use, and examples are illustrated in
FIGS. 1H-1T . The embodiments shown, with the exception ofFIGS. 1R and 1S , have an axis of symmetry. Several of the embodiments have an 9-fold rotational symmetry, for example, the embodiments ofFIGS. 1K and 1L . Other embodiments have a 6-fold rotational symmetry, for example, the embodiments ofFIGS. 1H, 1J, 1M and 1T . It is to be understood that other similar shapes, including but not limited to other axisymmetric shapes, may be used to create an energy-storage member with two stable configurations. Further, non-symmetric shapes may be used to create an energy-storage member with two stable configurations. It is also to be understood that the presence or absence, size, shape, and configuration of any slots or cutouts in the energy-storage member may be altered to allow the energy-storage member to have two stable configurations. It is also to be understood that the energy-storage member may comprise a plurality of individual energy-storage members that may or may not be identical in size, shape, and material. The usage of a plurality of individual energy-storage members is useful to allow alteration of applicator velocity, energy, activation force, or other performance characteristics in ways that may not be achievable with a single energy-storage member. - In operation, and with reference again to
FIGS. 1A-1E , an applicator comprising an energy-storage element is placed in contact with the skin such thatskin contacting element 12 is directly on the stratum corneum and, optionally, adhered to skin by means of adhesive disposed onelement 12. The energy-storage element is in a first stable configuration and is movable to a second stable configuration by application of force. Actuatingmember 20 is pressed downward, in the direction ofarrow 32. This causes actuatingmember 20 to move downward, engaginginner edge 30 of energy-storage member 28, and applying the force necessary to move the energy storage member into its second stable configuration, wherein theinner edge 30 of the member approaches the horizontal plane previously defined by the outer edge of the member (e.g.,FIGS. 1E-1F ). As a result of movement of the energy-storage member, a microarray in contact withholder 24 comes forcibly into contact with skin. - The process of inversion of energy storage member may be quite rapid, appearing for example instantaneous to the human eye. It may last, for example, no more than about 10 ms, no more than about 30 ms, or more than 100 ms, or no more than ½ second. The shape assumed by energy storage member following inversion may be the reflection of the original shape in a plane.
- The material from which the energy storage member is manufactured is variable, and a skilled artisan will appreciate that it is selected based on the several design considerations, including storage life and desired application force, which of course will also depend on the configuration of the member. Exemplary materials include metals, alloys, plastics, and specific examples include stainless steel and thermoplastics.
-
FIG. 2A depicts schematically in cross-section, with certain dimensions exaggerated for emphasis, another embodiment of an applicator, prior to actuation.Applicator 100 comprises three principal members, anactuator 102, ahousing 104, and apush member 106.Housing 104 comprises adistal edge 108 contoured for contact withskin 110.Housing 104 also has at least two projections extending from its inner circumferential surface, such asprojections push member 106, whereFIG. 2 shows matching projection 116 mating withprojection 112. Collectively the projections holdpush member 106 and resist the force of aspring 118 tending to push thepush member 106 down.Member 106 has aplanar base surface 120 onto which amicroprojection array 122 is affixable or affixed. - In order to cause
member 106 and the attachedmicroprojection array 122 to be driven towards theskin 110, it is necessary to dislodgemember 106 from the projections such as 112 and 114. In order to do that, actuatingmember 102 is used. It contains for each of the projections such as 112 and 114 a rod, such asrods projections member 106 is no longer held up by them, and thespring 118 is free to release its energy in order to movemember 106 downward. - The structure of
member 106 is further explained byFIG. 2B , which depicts schematically one quarter ofmember 106. It is seen that this quarter has abase 130, awall 132, acentral column 134 and aprojection 136, which is designed to engage with a projection on the applicator housing, such asprojection 112 seen inFIG. 2A . - In
FIGS. 2A-2B as indicated above the dimensions are exaggerated for clarity. In reality the projections onmembers actuation member 102 is pressed down. It would be expected that all threemembers - Many variations on
FIG. 2A are possible. For example, the number n of projections like 112 and 114 around the inner periphery ofmember 104 could be varied. They would generally be expected to be placed atpositions 360/n degrees apart, but it might be desired to space them more closely in some instances, for example with four projections at 0 degrees, 80 degrees, 180 degrees, and 260 degrees. - The skin-contacting
edge 108 ofhousing 104 could be provided with a skirt so that the area which contacts the skin is more extensive. The skin-contacting edge could be provided with an adhesive, which in turn would in storage conveniently be covered by an optional release liner. - In the device of
FIGS. 2A-2B , the energy needed to actuate is that required to flex inward the projections, such as projections 116 (FIG. 2A ) or 136 (FIG. 2B ) ofmember 106. This energy depends on their precise dimensions and the material characteristics (e.g., Young's modulus) of the material out of which they are made. If this pressure were sufficiently low that inadvertent actuation were a possibility, it might be desirable to place some kind of spring or spring-like object between the actuating member and the push member, so that an energy needed to deform this object must be supplied before actuation can occur. The use of such an object allows the user input force to be set at a level suitable for the target population without imposing limitations on the energy stored in the spring used to propel the microneedle array. - In further variants on the design of
FIGS. 2A-2B it is possible to use features in addition to or different from the projections to hold a push member and spring in place prior to actuation. A design of this type is depicted inFIGS. 3A-3B . - In
FIG. 3A , which is a schematic cross-section, is amember 164 which makes contact with skin. Engaged withmember 164 is aclip 168, which is depicted also in perspective inFIG. 3B .Clip 168 has a certain number of outward projections, such asprojection 172. In the embodiment shown, there are three such outward projections. These outward projections may generally flex in an approximately radial direction towards the center ofclip 168. These outward projections fit into openings inmember 164 as shown inFIG. 3A . Underneathmember 164 there is afurther member 166 which holds a microprojection array (which is not shown in the figure). Betweenmembers spring 170.Spring 170 serves as an energy-storing member. It tends to pushmember 166 downward. However, it is restrained by the projections like 172 ofclip 168. - In contact with
clip 168 is anactuation member 160. It has openings like 162, one for each of the outward projections like 172. The lower portions of these openings like 162 have a surface against which the projections like 172 press during storage. However, whenactuation member 160 is pushed downwards, eventually the projections like 172 are enabled to flex outwards, releasingmember 166 and allowingspring 170 to pushmember 166 downwards towards the skin. - Springs of different kinds (not shown in
FIG. 3A ) may be used to establish a minimum force which is necessary to push downmember 160 and actuate the applicator. Such springs may, for example, be located between the upper surface ofmember 164 and the lower (inner) surface ofactuation member 160. - The
clip 168 may be made of metal, while the remainder of the applicator is made of suitable polymers. By making the clip of metal, the vertical wall of the housing may be made thinner, a thick section on that wall not being needed to avoid creep. As may be seen from the description above, theprojections 172 in this embodiment extend further outward than the position shown inFIG. 3A , so that some force is required to push them in enough to fit the bottom of theopening 162 inhousing 160 as shown inFIG. 3A . -
FIGS. 4A-4B schematically disclose another embodiment of anapplicator 180, shown fully assembled inFIG. 4A and in exploded view inFIG. 4B . Anouter housing 182 is separated by an energy-storage member 183 from a microprojection-holdingmember 184 which holds a microprojection array (not shown in the figure). In this embodiment, the energy-storage member is in the form of a wave spring, as illustrated inFIG. 4B . A wave spring is preferred in some embodiments over other types of compressive springs due to its small size when compressed, which is of value for a disposable device. It is to be understood that other compressive springs are also suitable and the applicator of this embodiment is not limited to a wave spring. In storage, microprojection-holdingmember 184 is held in place by two platforms inhousing 182, such asplatform 196, against which a projection member, such asmembers member 184, engages. When it is desired to activate the device, a user twists member 184 (e.g., with thumb and forefingers grippingprojection members 185, 187) so that it is no longer over the platforms and restrained by them. When that twisting occurs,member 184 moves downward pressing the microprojections against the skin. - The applicator of
FIGS. 4A-4B is further provided with a set of components for adapting to skin, in this case anadapter 190, asnap ring 186, and anextender 188. This extender has the same function as the outwardly projecting flange seen inFIG. 3A as part ofmember 164. In addition,FIG. 4A shows an adhesive 192 and arelease liner 194. These kinds of components may also be used in connection with the other applicators described herein. The applicator ofFIGS. 4A-4B also includes an optional safety feature, in this embodiment in the form of apin 197 that is removably inserted through a cavity inmicroprojection holding member 184 prior to use. To enable the applicator for actuation, a user pullspin 197 from its retaining position as shown inFIG. 4A to permit a user to activate the applicator by the twisting motion described above. - In an alternative embodiment of the applicators of
FIGS. 4A-4B , theextender 188 of the applicator may have a frustoconical rather than a flat shape. - In another embodiment of the applicator of
FIGS. 4A-4B , the housing member may be provided with its own outward projection for adaptation to skin, as depicted inFIG. 5 . InFIG. 5 ,housing 220 comprises abase surface 222 with aprojection 224 designed for contact with skin when in use. Anouter portion 226 of theprojection 224 has a thickness less than aninner portion 228. Reinforcing elements, such aselement 230, are provided. Just as inFIGS. 4A-4B , there is anelongated opening 232 at the top ofhousing 220, where the opening comprises two platforms, such asplatform 234, against which the microprojection-holding member presses when the applicator is in storage. - A feature of merit for applicators is the skin penetration efficiency achieved with a particular microprojection array. An exemplary test for skin penetration efficiency requires the placement of the microneedle array upon a test sample of cadaver skin, the insertion of the array the applicator under testing, and the withdrawal of the array after a period of time. At that time the percentage of openings in the skin sample that are deemed to allow adequate transport of material may be taken as a figure of merit. A material that may be used to test adequacy of transport is India ink. It is desirable that at least about 80%, preferably at least about 90%, and more preferably at least about 95% of the openings in the skin allow adequate transport of material.
- The applicators described herein above can optionally include a safety mechanism or latch to prevent unintended actuation of the applicator and consequential deployment of the microneedle array. Various embodiments of a safety mechanism are now described.
- In a first embodiment, a pin or tab is used to prevent accidental actuation of the applicator. By way of example,
FIGS. 6A-6B illustrate a cantilevered pin safety mechanism, where a retainingmember 300 is dimensioned to snap fit on an applicator housing. Retainingmember 300 is shown inFIG. 6A positioned on an applicator housing, and is shown alone in an enlarged side view inFIG. 6B . One or more pins, such aspin 302, on the retaining member fit within a groove in the actuation member of an applicator, preventing deployment of the actuation member. Rotation of the retaining member in a clockwise or counterclockwise direction by pressing ontab 304 releases the pin from the retaining groove, to allow deployment of the actuation member. - Another example of a pin-type safety mechanism is illustrated in
FIGS. 7A-7B . Applicator 310 comprises ahousing 312 and anactuation member 314 movably inserted into an opening inhousing 312. Aslot 316 is formed inactuation member 314 at a position where the slot is in movable engagement with apin 318. When the pin is fully seated in the slot,actuation member 314 is in a locked position. A twisting motion of the housing or the actuation member unlocks the pin and slot, so that the actuation member can be deployed. -
FIGS. 8A-8B illustrate other examples of tab safety mechanisms, where inFIG. 8A acantilevered push tab 320 is movable to displace apin 322 that locks anactuation member 324 in place.FIG. 8B shows a twist tab orsnap tab 326 that interferes with movement of theactuation member 328. Removing the twist tab by twisting until it breaks off releases the safety mechanism and allows actuation of the applicator. - In a second embodiment, a safety mechanism in the form of a protective cap is provided, to prevent inadvertent actuation of an applicator comprising a microneedle array. An example is provided in
FIGS. 9A-9B , wherecap 350 is shown in a closed position (FIG. 9A ) and in an open position (FIG. 9B ).Cap 350 comprises a retainingmember 352 and acup member 354 connected to the retaining member by aflexible bridge member 356. Barbs or hooks extend from the retaining member, to fix the cap onto an applicator, as depicted inFIG. 9B . The cup member shields an actuation member on the applicator, preventing inadvertent application of force to the actuation member, and consequential deployment of the microneedle array. -
FIGS. 10A-10B illustrate another embodiment of a cap type safety mechanism, where apeel cap 360 fits snugly about the outer periphery of an applicator, preventing access to the actuation member of the applicator. Removal of the peel cap exposes the actuation member, rendering it available for use. - In another embodiment, the applicator described herein is designed to prevent unintended actuation of the applicator and consequential deployment of the microneedle array in accord with the design depicted in
FIGS. 11A-11B .FIG. 11A depicts anapplicator 400 in a configuration prior to deployment or actuation by a user.FIG. 11B depicts the same applicator after deployment or actuation by a user.Applicator 400 is comprised of arigid housing 402 comprised of afirst member 404 and asecond member 406. In other embodiment, the housing is semi-rigid, semi-flexible, or flexible. First and second members are configured to engage one another so as to fit together in a secure configuration, such as by a snap-fit mechanism or an insertable lip/groove mechanism (seen, for example, inFIG. 12A ). First member orupper housing member 404 has acentral opening 408 in which anactuating member 410 slidingly fits. Second member orskin contacting member 406 is hollow or open, to receive the actuating member upon actuation of the applicator, as seen inFIG. 11B . Prior to actuation of the application (FIG. 11A ), the plane of the top surface of actuating member, denoted by dashedline 412 inFIG. 11A , is co-planar or slightly under/lower than the plane of the uppermost edge of thefirst member 404 ofhousing 402, denoted by dashedline 414 inFIGS. 12A-12B , which are cross-sectional views of an exemplary applicator. In this configuration, the external, upper surface of the actuating member is co-planar with the uppermost surface of the housing, so that the actuating member is nested into or recessed into the housing prior to its actuation. After actuation of the actuating member, wherein the actuating member is deployed to a second position, the actuating member is depressed into the housing and the upper surface of the actuating member approaches a plane defined by an upper rim of thesecond housing member 406, denoted by dashedline 416 inFIGS. 12A-12B . As can be appreciated, the design wherein the actuating member is nested into the housing prior to actuation (e.g., the actuating member does not extend outward from the housing) prevents inadvertent deployment of the applicator. - The internal components of an applicator wherein the actuating member's upper external surface is flush with the uppermost (proximal with respect to the skin contacting surface of the housing) surface of housing can vary, and two embodiments are shown in
FIGS. 12A-12B andFIGS. 13A-13B , wherein like elements with respect toFIGS. 11A-11B are given like numerical identifiers despiteFIGS. 12A-12B andFIGS. 13A-13B being different embodiments. InFIGS. 12A-12B ,applicator 400 is shown in a side cross-sectional view.First member 404 ofhousing 402 has anupper rim 420 that defines an uppermost plane of the applicator, the upper plane denoted by the dashedline 414. Actuatingmember 410 is movably positioned in the housing, movable between first and second positions, where in its first position the upper surface of the actuating member, denoted by the plane indicated by dashedline 412, is co-planar with the upper plane of the applicator or is slightly lower than the upper plane of the applicator, as seen inFIG. 12A . Upon application of a force, depicted byarrow 422, by a user, the actuating member travels to its second position, for deployment into the skin of a user of a microneedle array (not shown) positioned on a holdingmember 424 engaged with the actuating member. In its second, deployed position, the upper surface of the actuating member approaches, contacts, or travels beyond, a plane defined by an upper rim of thesecond housing member 406, the plane denoted by dashedline 416. - With continuing reference to
FIGS. 12A-12B , actuatingmember 410 travels from its first to second positions along a plurality of guide fins, such asfins groove 430, is disposed in actuating member. Grooves or slots are similarly provided in the first and second members of the housing, to secure each guide fin in the applicator. The plurality of guide fins guide the plunger of the actuating member relative to the housing to maintain alignment during activation of the device. Each guide fin is dimensioned with sufficient thickness to avoid sharp edges, and the edges can be curved with a radius of curvature to ensure no sharp edging. It is also desirable that each guide fin have a horizontal axis of symmetry that allows for its insertion into the housing in either direction. -
FIGS. 13A-13B are cross-sectional side views of another embodiment of the applicator ofFIGS. 11A-11B , whereinFIG. 13A shows the applicator prior to activation andFIG. 13B shows the applicator after its activation. In this embodiment, the applicator prior to activation has an actuatingmember 410 that is recessed within the housing, as evident from the fact that the upper surface of the actuating member is below or under the upper rim of thefirst housing member 404, as illustrated by the respective dashed lines 412 (corresponding to the plane defined by the upper surface of the actuating member) and 414 (corresponding to the plane defined by the plane defined by upper rim of the first housing member). As seen inFIG. 13B , activation of the actuating member by application of a force moves the actuating member to its second position, wherein the upper surface of the actuating member is closer (relative to the upper surface of the actuating member in its first position) to theupper rim 407 of thesecond housing member 406, denoted by dashedline 416. The actuating member travels from its first to second positions along a plurality of guide posts, such asposts -
FIGS. 12A-12B and 13A-13B also illustrate theenergy storage element 436 positioned with the applicator. As discussed in detail above, the energy storage element moves from a first position to a second position upon application of a force by the actuating member. Movement from its first to its second position occurs only upon application of a sufficient force, and results in an inversion of the element. The element is stable in both its first and second positions in that it does not of its own accord move between the positions, but requires application of force to move from its first to its second position, and from its second position to its first position. In a preferred embodiment, the force required to move the element from its second to its first position is less than the force required to move the element from its first to its second position. Absent application of force, the element cannot return to its first position subsequent to actuation of the device. Prior to activation of the applicator, the energy storage element contacts the second housing member that is in contact with the skin, and after activation, the energy storage element is in contact with the first member of the housing (also referred to as an outer cover). Activation of the actuation member releases energy stored in the energy storage element, the release energy acting on the microprojection holding member in contact with the actuating member. - In another aspect, a method for administering an active agent to a subject is provided. The method comprises providing a microprojection array in conjunction with any one of the applicators described herein, the microprojection array comprising an active agent. The agent is delivered transdermally by actuation of the applicator, to deploy the microprojection array into contact with the skin, or more generally a membrane or body surface, of a subject. The active agent to be administered can be one or more of any of the active agents known in the art, and include the broad classes of compounds such as, by way of illustration and not limitation: analeptic agents; analgesic agents; antiarthritic agents; anticancer agents, including antineoplastic drugs; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics, antifungal agents, antiviral agents and bacteriostatic and bactericidal compounds; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; anxiolytics; appetite suppressants; attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular preparations including calcium channel blockers, antianginal agents, central nervous system agents, beta-blockers and antiarrhythmic agents; caustic agents; central nervous system stimulants; cough and cold preparations, including decongestants; cytokines; diuretics; genetic materials; herbal remedies; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; keratolytic agents; leukotriene inhibitors; mitotic inhibitors; muscle relaxants; narcotic antagonists; nicotine; nutritional agents, such as vitamins, essential amino acids and fatty acids; ophthalmic drugs such as antiglaucoma agents; pain relieving agents such as anesthetic agents; parasympatholytics; peptide drugs; proteolytic enzymes; psychostimulants; respiratory drugs, including antiasthmatic agents; sedatives; steroids, including progestogens, estrogens, corticosteroids, androgens and anabolic agents; smoking cessation agents; sympathomimetics; tissue-healing enhancing agents; tranquilizers; vasodilators including general coronary, peripheral and cerebral; vessicants; and combinations thereof.
- In preferred embodiments is a protein or a peptide. In another embodiment, the agent is a vaccine. Example 1 below details administration of human parathyroid hormone to porcine skin in vitro. Examples 2-4 detail administration of human parathyroid hormone to human subjects. Additional details of administration of human parathyroid hormone to human subjects using a microprojection array, including detailed pharmacokinetic analysis, are given in provisional application No. 61/331,226, filed May 4, 2010; the entire contents of this co-filed application are incorporated by reference herein. Additional examples of peptides and proteins which may be used with microneedle arrays are oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone, follicle stimulating hormone, luliberin or luteinizing hormone releasing hormone (LHRH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, tumor necrosis factor, colony stimulating factors, motilin, bombesin, dinorphin, neurotensin, cerulein, bradykinin, urokinase, kallikrein, substance P analogues and antagonists, angiotensin II, nerve growth factor, blood coagulation factors VII and IX, lysozyme chloride, renin, bradykinin, tyrocidin, gramicidines, growth hormones, melanocyte stimulating hormone, thyroid hormone releasing hormone, thyroid stimulating hormone, pancreozymin, cholecystokinin, human placental lactogen, human chorionic gonadotropin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, platelet derived growth factor, growth hormone releasing factor, bone morphogenic protein, and synthetic analogues and modifications and pharmacologically active fragments thereof. Peptidyl drugs also include synthetic analogs of LHRH, e.g., buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide (leuprorelin), lutrelin, nafarelin, tryptorelin, and pharmacologically active salts thereof. Administration of oligonucleotides are also contemplated, and include DNA and RNA, other naturally occurring oligonucleotides, unnatural oligonucleotides, and any combinations and/or fragments thereof. Therapeutic antibodies include Orthoclone OKT3 (muromonab CD3), ReoPro (abciximab), Rituxan (rituximab), Zenapax (daclizumab), Remicade (infliximab), Simulect (basiliximab), Synagis (palivizumab), Herceptin (trastuzumab), Mylotarg (gemtuzumab ozogamicin), CroFab, DigiFab, Campath (alemtuzumab), and Zevalin (ibritumomab tiuxetan).
- It is to be understood that while the subject matter has been described in conjunction with the preferred specific embodiments thereof, the foregoing description is intended to illustrate and not limiting in scope. Other aspects, advantages, and modifications will be apparent to those skilled in the art to which the subject matter pertains.
- All patents, patent applications, and publications mentioned herein are hereby incorporated by reference in their entireties. However, where a patent, patent application, or publication containing express definitions is incorporated by reference, those express definitions should be understood to apply to the incorporated patent, patent application, or publication in which they are found, and not to the remainder of the text of this application, in particular the claims of this application.
- The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject matters described herein, and are not intended to limiting in the scope of the subject matter. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. and pressure is at or near atmospheric.
- Three slotted spring applicators designated B1, B2 and B3, similar to those depicted in
FIGS. 1A-1F , were compared with an applicator designated “A” of the type depicted inFIGS. 4A-4B for skin penetration efficiency and ability to deliver hPTH(1-34) (human parathyroid hormone 1-34 fragment, also referred to as teriparatide when produced recombinantly). The applicators B1, B2 and B3 differed in the precise characteristics of the slotted spring energy-storing element (dimensions and material). Applicator B1 was 0.012 inches thick stainless steel, Applicator B2 was 0.0155 inches thick and made of 17-7 stainless steel, and Applicator B3 was 0.0155 inches thick and made of 301 stainless steel. The B1 slotted springs had somewhat longer indentations from the outside in comparison to the B2 and B3 slotted springs. - Microprojection arrays were fabricated from Dextran-70 and containing hPTH(1-34), as described in U.S. Publication No. 2008-0269685. The sequence of hPTH(1-34) used was:
-
(SEQ ID NO: 1) H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn- Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg- Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp- Val-His-Asn-Phe-OH - The microneedles were 4-sided pyramids with spacing 200 microneedle height 250 and array diameter 11 mm, with 2742 microneedles per array.
- Testing was done with porcine skin smoothed flat on a polyurethane foam backing. The apparent dose delivered was determined by analyzing the residual amount of hPTH(1-34) in the arrays and on skin. Results are shown in the table.
-
Device % Apparent Dose % Delivery Efficiency ID Rep # SPE1 μg Mean SD % Mean SD A Rep 1 94.3 32.4 32.0 0.6 86.4 85.2 1.7 Rep 298.9 31.5 84.0 B1 Rep 1 83.3 18.9 23.0 5.7 50.4 61.3 15.1 Rep 290.4 17.4 46.4 Rep 3 96.9 26.7 71.2 Rep 4 93.7 28.9 77.1 B2 Rep 1 99.9 18.5 27.7 6.2 49.3 73.7 16.4 Rep 2101.1 30.2 80.5 Rep 3 100 30.0 80.0 Rep 4 99.5 31.9 85.1 B3 Rep 1 92.9 8.9 19.3 8.6 23.7 51.3 22.9 Rep 2100.8 27.0 72.0 Rep 3 94.8 15.5 41.3 Rep 4 96.4 25.6 68.3 1SPE = skin penetration efficiency - Skin penetration efficiency (SPE) is estimated by counting the number of holes in the microneedle-treated skin region relative to the number of microneedles on the array used to treat the skin. It is believed that certain weaker results for SPE, such as the first replication of the B1 applicator, could be due to a possible error installing the slotted spring upside down into the plastic housing.
- A microprojection array containing a therapeutically effective amount of hPTH(1-34) (32 μgrams) was prepared for use in a Phase I clinical study as follows.
- First, in describing generally the features of the microprojection array, the microprotrusions of the array can be characterized generally as comprising a DIT (drug-in-tip) layer and a “backing” layer. The DIT layer includes hPTH(1-34) in a water-soluble matrix. The sequence of hPTH(1-34) used is as follows:
-
(SEQ ID NO: 1) H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn- Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg- Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp- Val-His-Asn-Phe-OH - The tip of the microprojections is also referred to herein as the layer at the bottom-most portion of the tips or microprotrusions (i.e., proximal to the skin when placed upon the skin), also referred to herein as the “end portion” that is distal to the base of the array). The “backing” layer as referred to in certain of these examples, encompasses both the upper portion of the microprotrusions proximal to the base of the array as well as the base itself, where the base is the portion of the array that supports the tips. The backing layer comprises a biocompatible, non-water soluble matrix. In the instant array device, the material in the upper portion of the microprotrusions is the same as the base material itself, so that the non-water soluble matrix formulation is applied as a single layer to fill the mold atop the DIT layer.
- The DIT layer of the microstructure array dissolves into the skin and contains the components provided in Table 2-1. Acetate was the counter-ion in the hPTH(1-34) drug substance.
-
TABLE 2-1 Composition of Drug-in-Tip Layer of hPTH(1-34) TDS % w/w (of the Trade Chemical Name Quantity Range microstructure Name of Ingredient (μg/unit) (μg/unit) array) hPTH (1-34) human Parathyroid 32.0 25.6-38.4 12.8 hormone (1-34) Dextran 70Dextran, 70,000 Dalton 160.0 128.0-192.0 58.6 molecular weight Sorbitol, Sorbitol 54.9 64.0-96.0 21.9 N.F. Histidine L-histidine 0.14 0.11-0.17 0.1 Histidine L-histidine hydrochloride 0.73 0.58-0.88 0.3 HCl NA Acetate 2.5 2.0-3.0 1.0 Total 250.27 100.0 - The backing portion or layer of the array was composed of poly(DL-lactide-co-glycolide), 75:25, ester terminated (Tradename: LACTEL®).
- The ingredients forming the tip portion of the formulation (i.e., the DIT formulation) were dissolved in water, cast, and dried in a silicone mold containing microstructure cavities to form the drug-in-tips (DIT) structures. The water insoluble, biocompatible polymer, poly(DL-lactide-co-glycolide), 75:25, was dissolved in acetonitrile to provide the backing formulation which was then coated on top of the DIT layer in the silicone mold, and then dried. The solvent was removed from the backing (upper portion proximal to the base, and base) during processing and was limited to a level below the amounts recommended in ICH guidelines.
- The final transdermal/microneedle delivery system product (sometimes abbreviated herein “TDS”) was assembled and contained the microprojection array described above in Example 2. The product was designed to deliver a systemic dose of hPTH (1-34) across the stratum corneum barrier layer of the skin using an array of microstructures. The final TDS product was formed by the integration of two components, a plunger-array assembly containing drug product and an applicator assembly, where these two items were packaged separately and integrated at the clinical site (See Example 4 below for clinical data).
- The microprojection array contained in the plunger-array assembly possesses an 11 millimeter diameter of approximately 2700 microstructures arranged in a hexagonal pattern. The plunger-array assembly consists of the microprojection array mounted to an array support member, in this case, as plastic plunger with an adhesive laminate. The plunger-array assembly was packaged inside a protective container and pouched in a dry nitrogen environment.
- The applicator assembly includes a plastic shell or housing with skin contact adhesive and a release liner, an energy storage member (in this case, a metal spring) to provide the energy needed to accelerate the plunger-array assembly, and elements to hold these items together until assembly at the clinic with the plunger-array assembly. This unit is packaged inside a protective container and pouched.
- The final assembled drug product consists of the plunger-array assembly which is inserted into the applicator assembly. The TDS is activated by compressing the spring and then twisting the plunger to lock and hold the compressed spring in place until use. When activated, the spring delivers the stored energy to the plunger causing it to accelerate and contact the skin. Upon contact with the skin, the microstructures penetrate past the stratum corneum, and the hPTH dissolves into the skin rapidly. Following actuation of the spring and delivery of hPTH, the device is removed and discarded. The applicator assembly and plunger-array assembly as well as the final assembled TDS product correspond to those shown in
FIGS. 4A-4B . - An open label, single dose, sequence randomized, 3-way cross-over study was carried out in sixteen healthy female volunteers to determine the pharmacokinetics (along with additional secondary endpoints) of 32 μg hPTH(1-34) and 64 μg hPTH(1-34) (32 μg hPTH(1-34)×2) delivered using the microneedle transdermal delivery system identified by the tradename MicroCor®, described in Examples 2 and 3 relative to subcutaneously administered (SC) hPTH (teriparatide) commercially available under the tradename FORTEO®, 20 μg. One subject was withdrawn after the first treatment due to difficulty in bleeds resulting from venous spasms. The product described in Examples 2 and 3 is referred to in this example generally as “MicroCor® hPTH(1-34)” or simply, “MicroCor®”.
- Subjects received a single dose of 32 μg hPTH(1-34) or 64 μg hPTH(1-34) (32 μg×2) by applying the MicroCor® device to an abdominal site for 5 minutes. Treatment with FORTEO® was accomplished by administration as a subcutaneous injection into the abdominal wall. Treatments were separated by a 48-hour washout period. The plasma sampling schedule was as follows: pre-treatment, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 120, 180, 240, 300, 360 minutes, and 24 hours post-treatment. Vital signs were monitored pre-treatment, and at 15 and 30 minutes, and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-treatment. Adverse advents were monitored throughout the study. Additional assessments included (i) measurement of anti-PTH antibodies prior to first treatment and 2 weeks following last treatment, (ii) measurement of serum calcium, phosphorous, albumin, and protein at pre-treatment, and 1, 2, 3, 4, 5, 6, and 24 hours post-treatment, as well as (iii) MicroCor® adhesion. The following tables summarize study results.
-
TABLE 4-1 Local Skin Tolerability MicroCor ® (N = 17; 49 FORTEO ® Symptoms Observation applications) (N = 16) Evidence Yes 0 1 (6.3%) of bleeding No 49 (100%) 15 (93.7%) Discomfort at None 9 (18.4%) 10 (62.5%) application Mild 31 (61.2%) 5 (31.3%) Moderate 10 (20.4%) 1 (6.3%) Discomfort None 26 (53.1%) N/A pre-removal Mild 21 (42.9%) (MicroCor ® only) Moderate 2 (4.1%) Discomfort None 44 (89.8%) N/A at removal Mild 5 (10.2%) (MicroCor ® only) -
TABLE 4-2 Pharmacokinetic Results MicroCor ® MicroCor ® Parameter 32 μg 64 μg FORTEO ® AUC/Dose 220 (n = 15) 229 (n = 16) 429 (n = 16) (pg*min/mL*mcg) Cmax (pg/mL) 180 (n = 16) 336 (n = 16) 85 (n = 16) Tmax (minutes) 8.1 (n = 16) 7.4 (n = 16) 26.2 (n = 16) T1/2 (minutes) 37.1 (n = 16) 52.0 (n = 16) 52 (n = 16) Time to reach 50% ~20 ~20 ~90 minutes of Cmax (plasma normalized), minutes - Application of hPTH with the MicroCor device demonstrated good skin tolerability. Skin effects were transient and well-tolerated, with mild to moderate erythema observed.
- In terms of general safety, all treatment regimes were well-tolerated. No significant adverse events nor unexpected adverse events occurred. In fact, there was no difference in the overall treatment-related adverse events between application of the hPTH via the MicroCor® device and the Forteo®-based treatment. No significant changes were observed in serum calcium, and no anti-PTH antibodies were detected—again, further demonstrating the overall safety of MicroCor®-based treatment in human subjects.
- As can be seen from the data summarized in Table 4-2, relative to the Forteo® product, the MicroCor® delivery system exhibits rapid pharmacokinetic properties such as a shorter Tmax, a higher Cmax, and a shorter elimination half life, T1/2, as compared to a subcutaneous injection of the agent. Absorption of hPTH (1-34) occurred more rapidly with the MicroCor® delivery system relative to the Forteo® product, as illustrated by the higher dose-normalized Cmax value and the faster Tmax values for both MicroCor® treatments. The half-life based upon administration via the MicroCor® device as also shorter than with Forteo®. Moreover, application using the MicroCor® device was more effective in achieving the desired pulsatile delivery profile of hPTH(1-34) (i.e., rapid on set and rapid offset after reaching Cmax).
- The MicroCor®-based delivery results in faster elimination of drug. Based upon a plot of plasma concentration (normalized) versus time, it can be seen that the time to reach 50% of Cmax for the MicroCor®-based treatments was approximately 20 minutes for both the 32 and 64 microgram treatments (i.e., based upon the time to reach a normalized plasma concentration of 0.5). In contrast, the time to reach 50% of Cmax for the Forteo®-based treatment was approximately 1.5 hours (90 minutes), based upon time post-administration. Thus, the time to reach 50% of Cmax for the MicroCor®-based treatments was approximately 4.5 times less than that observed for subcutaneously injected PTH)(Forte® indicating notably faster elimination of drug when administered transdermally from a microneedly array as in the MicroCor® system.
- Finally, based upon a residual analysis of the PTH content of the MicroCor® delivery system following delivery of drug, it was determined that, on average, about 85% of drug was delivered from the device (i.e., 85% delivery efficiency).
Claims (23)
1. An applicator for a microprojection array, comprising:
an energy-storing element having a first stable configuration and second stable configuration, wherein application of force to the energy-storing element causes it to transition from the first stable configuration to the second stable configuration, and wherein the force necessary for the energy storing element to transition from the first stable configuration to the second stable configuration is lower than the force necessary for the element to transition from the second stable configuration to the first stable configuration;
an actuating member that can convey external force to the energy-storing element,
a microprojection-holding member connected to the actuating member and which is acted on by the energy-storing element when it transitions from the first stable configuration to the second stable configuration,
an outer cover with an opening into which the actuating member fits slidably,
a skin-contacting member comprising a portion which can lie flat against skin, wherein the skin-contacting member fits the outer cover and contacts the energy-storing element when it is in its first configuration.
2. The applicator of claim 1 , wherein the energy-storing element has an axis of symmetry and n-fold rotational symmetry for some integer n.
3. The applicator of claim 2 , wherein the energy-storing element transitions from the first stable configuration to the second stable configuration upon application of force in a direction of the axis of symmetry.
4. The applicator of any claim 2 , wherein the value of n is between 3 and 6.
5. The applicator of claim 2 , wherein the energy-storing element is of generally frustoconical shape with slots from the top of the frustum, from the bottom of the frustum, or from both.
6. The applicator of claim 1 , wherein upon application of force to the actuator member the energy-storing element transitions from its first stable configuration, wherein it is in contact with the skin-contacting member, to its second stable configuration wherein it is in contact with the outer cover.
7. The applicator of claim 1 , wherein the outer cover is manufactured from a rigid material.
8. The applicator of claim 1 , wherein the actuator member moves within the outer cover between a first position and a second position, wherein in its first position the actuator member extends from an upper surface of the outer cover.
9. The applicator of claim 1 , wherein the actuator member moves within the outer cover between a first position and a second position, wherein in its first position the actuator member is recessed within the outer cover.
10. The applicator of claim 1 , wherein a microprojection array is attached to the microprojection-holding member, the microprojection array comprises a base, and the level of the microprojection array's base is below a skin-contacting surface of the skin-contacting member following actuation of the actuating member.
11. The applicator of claim 1 , wherein the energy-storing element is in mechanical coupling relationship with the microprojection-holding member when the energy-storing element is in its first stable configuration.
12. An applicator for a microprojection array, comprising:
(a) a housing having a surface with an elongated opening having platforms on opposite sides of the opening,
(b) an actuation member comprising a surface upon which a microprojection array can be attached, a generally washer-shaped surface on which an energy-storage member can be placed, and a surface capable of mating with the platforms on the opening of the housing and capable of fitting through the opening,
(c) an energy-storage member situated between the actuation member and the housing,
(d) a skin-contacting area which is generally washer-shaped connected to the housing,
wherein when the actuation member is mated with the platforms on the opening, the energy-storage member has a first force of stored energy, and
wherein when the actuation member is moved within the opening so that it no longer mates with the platforms, the energy-storage member releases its stored energy and in so doing moves the actuation member.
13. The applicator of claim 12 , wherein the energy-storage member when mated with the platforms on the opening has a first force of stored energy by virtue of its being compressed.
14. An applicator, comprising:
(a) a housing having a first member with a central opening and a second member having a skin contacting surface,
(b) an actuation member disposed in the central opening and comprising a surface upon which a microprojection array can be attached and a groove extending circumferentially,
(c) an energy-storage member having an inner edge and an outer edge, and situated within the housing initially in a first stable configuration such that the inner edge is disposed in the groove and its outer edge is in contact with the second member,
wherein application of force to the actuation member moves the energy-storage member from its first stable configuration to a second stable configuration wherein the outer edge is no longer in contact with the second member.
15. The applicator of claim 14 , wherein the outer edge of the energy storage member in its second stable configuration is in contact with the first member.
16. The applicator of claim 14 , wherein a microprojection array holder engages the actuation member, the engagement of the actuation member and the microprojection array holder defining the groove.
17. The applicator of claim 14 , wherein the energy-storage member has an axis of symmetry and n-fold rotational symmetry for some integer n, wherein application of force in a direction of the axis of symmetry causes the energy-storing element to transition from the first stable configuration to the second stable configuration, and wherein the force necessary for the energy storing element to transition from the first stable configuration to the second stable configuration is lower than the force necessary for the element to transition from the second stable configuration to the first stable configuration.
18. The applicator of claim 17 , wherein the energy-storing element is of generally frustoconical shape with slots from the top of the frustum, from the bottom of the frustum, or from both.
19. An applicator according to claim 12 , further comprising a safety mechanism to prevent movement of the actuation member in a direction that deploys the microprojection array.
20. The applicator of claim 17 , wherein the safety mechanism comprises a protective cap over the applicator housing.
21. The applicator of claim 17 , wherein the safety mechanism comprises a pin movably inserted into the actuation member on an applicator.
22. A device comprising an applicator of claim 1 and a microprojection array comprising an active agent.
23. A method of administering an active agent to a patient in need of that agent, comprising placing a device according to claim 22 on a body surface of a patient, and activating the applicator by contacting the actuator.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/318,603 US20230277829A1 (en) | 2010-05-04 | 2023-05-16 | Applicators for microneedles |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33117510P | 2010-05-04 | 2010-05-04 | |
US13/100,924 US9687640B2 (en) | 2010-05-04 | 2011-05-04 | Applicators for microneedles |
US15/633,583 US10946180B2 (en) | 2010-05-04 | 2017-06-26 | Applicators for microneedles |
US17/185,746 US11666740B2 (en) | 2010-05-04 | 2021-02-25 | Applicators for microneedles |
US18/318,603 US20230277829A1 (en) | 2010-05-04 | 2023-05-16 | Applicators for microneedles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/185,746 Continuation US11666740B2 (en) | 2010-05-04 | 2021-02-25 | Applicators for microneedles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230277829A1 true US20230277829A1 (en) | 2023-09-07 |
Family
ID=44902422
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/100,924 Active 2035-03-13 US9687640B2 (en) | 2010-05-04 | 2011-05-04 | Applicators for microneedles |
US15/633,583 Active 2032-11-08 US10946180B2 (en) | 2010-05-04 | 2017-06-26 | Applicators for microneedles |
US17/185,746 Active 2032-02-16 US11666740B2 (en) | 2010-05-04 | 2021-02-25 | Applicators for microneedles |
US18/318,603 Abandoned US20230277829A1 (en) | 2010-05-04 | 2023-05-16 | Applicators for microneedles |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/100,924 Active 2035-03-13 US9687640B2 (en) | 2010-05-04 | 2011-05-04 | Applicators for microneedles |
US15/633,583 Active 2032-11-08 US10946180B2 (en) | 2010-05-04 | 2017-06-26 | Applicators for microneedles |
US17/185,746 Active 2032-02-16 US11666740B2 (en) | 2010-05-04 | 2021-02-25 | Applicators for microneedles |
Country Status (14)
Country | Link |
---|---|
US (4) | US9687640B2 (en) |
EP (1) | EP2566568B1 (en) |
JP (1) | JP5968875B2 (en) |
KR (1) | KR101808635B1 (en) |
CN (2) | CN102971038B (en) |
AU (1) | AU2011248166B2 (en) |
BR (1) | BR112012028263B1 (en) |
CA (1) | CA2801247C (en) |
ES (1) | ES2734560T3 (en) |
IL (1) | IL222803A (en) |
MX (1) | MX351458B (en) |
RU (1) | RU2569029C2 (en) |
WO (1) | WO2011140240A2 (en) |
ZA (1) | ZA201209035B (en) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
WO2008130587A2 (en) | 2007-04-16 | 2008-10-30 | Corium International, Inc. | Solvent-cast microneedle arrays containing active |
US8911749B2 (en) | 2007-04-16 | 2014-12-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
US9220678B2 (en) | 2007-12-24 | 2015-12-29 | The University Of Queensland | Coating method |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
EP3566649B1 (en) | 2009-03-02 | 2023-06-07 | YourBio Health, Inc. | Devices for blood sampling |
US9041541B2 (en) | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
US9033898B2 (en) | 2010-06-23 | 2015-05-19 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
US9119578B2 (en) | 2011-04-29 | 2015-09-01 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
RU2569029C2 (en) | 2010-05-04 | 2015-11-20 | Кориум Интернэшнл, Инк. | Microneedle applicators |
EP2566501B1 (en) | 2010-05-04 | 2019-03-13 | Corium International, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
WO2012006677A1 (en) | 2010-07-14 | 2012-01-19 | The University Of Queensland | Patch applying apparatus |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
US9017289B2 (en) * | 2010-11-03 | 2015-04-28 | Covidien Lp | Transdermal fluid delivery device |
KR102237667B1 (en) * | 2011-04-29 | 2021-04-12 | 세븐쓰 센스 바이오시스템즈, 인크. | Delivering and/or receiving fluids |
EP3106092A3 (en) | 2011-04-29 | 2017-03-08 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
TW201309351A (en) * | 2011-06-28 | 2013-03-01 | Bioserentach Co Ltd | Microneedle combination preparations for skin treatment |
EP2764887B1 (en) | 2011-10-06 | 2020-12-02 | Hisamitsu Pharmaceutical Co., Inc. | Applicator |
EP3881781B1 (en) | 2011-10-12 | 2023-03-29 | Vaxxas Pty Limited | Delivery device |
AU2015227524B2 (en) * | 2011-10-12 | 2017-05-18 | Kindeva Drug Delivery L.P. | Integrated microneedle array delivery system |
AU2015227515B2 (en) * | 2011-10-12 | 2017-05-18 | Kindeva Drug Delivery L.P. | Integrated microneedle array delivery system |
CN103857423B (en) * | 2011-10-12 | 2016-09-07 | 3M创新有限公司 | The microneedle array delivery system of one |
CA2857502C (en) * | 2011-11-30 | 2019-08-13 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
WO2013151044A1 (en) | 2012-04-05 | 2013-10-10 | 久光製薬株式会社 | Puncture device and method for manufacturing same |
EP2662110A1 (en) * | 2012-05-10 | 2013-11-13 | Debiotech S.A. | Device and method for inserting needles |
JP5903016B2 (en) | 2012-06-27 | 2016-04-13 | コスメディ製薬株式会社 | Protective release sheet for microneedle patch |
WO2014059104A1 (en) * | 2012-10-10 | 2014-04-17 | 3M Innovative Properties Company | Applicator and method for applying a microneedle device to skin |
EP2906284B8 (en) | 2012-10-10 | 2021-01-20 | Kindeva Drug Delivery L.P. | Force-controlled applicator for applying a microneedle device to skin |
US9789299B2 (en) | 2012-11-16 | 2017-10-17 | 3M Innovative Properties Company | Force-controlled applicator for applying a microneedle device to skin |
US9913970B2 (en) | 2012-12-21 | 2018-03-13 | Hisamitsu Pharmaceutical Co., Ltd. | Applicator |
BR112015014969B1 (en) | 2012-12-21 | 2021-12-07 | Corium, Inc | MICROSTRUCTURE APPARATUS AND METHOD OF MANUFACTURING A MICROSTRUCTURE APPARATUS |
CN109621083B (en) * | 2013-02-28 | 2022-03-22 | 索伦托治疗有限公司 | Drug delivery device |
EP2968887B1 (en) | 2013-03-12 | 2022-05-04 | Corium, Inc. | Microprojection applicators |
CN105246458B (en) | 2013-03-15 | 2020-09-15 | 考里安公司 | Microarrays for therapeutic agent delivery and methods of use thereof |
US10195409B2 (en) | 2013-03-15 | 2019-02-05 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
CA2903763C (en) | 2013-03-15 | 2021-11-16 | Corium International, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
CA2903583C (en) | 2013-03-15 | 2021-12-28 | Corium International, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
AU2014237499B2 (en) | 2013-03-15 | 2018-11-15 | Corium Pharma Solutions, Inc. | Microstructure array for delivery of active agents |
WO2014153447A2 (en) * | 2013-03-22 | 2014-09-25 | 3M Innovative Properties Company | Microneedle applicator comprising a counter assembly |
CN105263562B (en) | 2013-05-31 | 2018-09-21 | 3M创新有限公司 | Microneedle injection and infusion apparatus and its application method |
KR101615592B1 (en) | 2013-05-31 | 2016-04-26 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Microneedle injection apparatus comprising an inverted actuator |
JP6494602B2 (en) | 2013-05-31 | 2019-04-03 | スリーエム イノベイティブ プロパティズ カンパニー | Microneedle injection device with double cover |
EP3027263A1 (en) * | 2013-07-30 | 2016-06-08 | ZP Opco, Inc. | Low-profile microneedle patch applicator |
WO2015068702A1 (en) | 2013-11-05 | 2015-05-14 | 久光製薬株式会社 | Applicator |
CN103654969B (en) * | 2013-12-24 | 2015-12-30 | 湖州美奇医疗器械有限公司 | A kind of medical treatment helps pin device |
WO2015138207A1 (en) * | 2014-03-10 | 2015-09-17 | 3M Innovative Properties Company | Micro-needle device |
DK3117867T3 (en) * | 2014-03-12 | 2019-10-21 | Labo Juversa Co Ltd | Micro-needle preparation administration member for intradermal placement of target substance and apparatus for rapid administration of micro-needle preparation |
WO2015168217A1 (en) * | 2014-04-30 | 2015-11-05 | Kimberly-Clark Worlwide, Inc. | Cartridge portion of transdermal drug delivery apparatus and methods |
EP4218724A3 (en) | 2014-08-29 | 2023-08-16 | Corium Pharma Solutions, Inc. | Microstructure array for delivery of active agents |
EP3188714A1 (en) | 2014-09-04 | 2017-07-12 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
AU2016214968B2 (en) * | 2015-02-02 | 2021-02-25 | Vaxxas Pty Limited | Microprojection array applicator and method |
EP3260159A1 (en) | 2015-02-13 | 2017-12-27 | MEDRx Co., Ltd. | Microneedle insertion device and microneedle patch application device |
EP3280484A1 (en) * | 2015-04-07 | 2018-02-14 | LTS Lohmann Therapie-Systeme AG | Microneedle system for administering liquid formulations |
US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
JP6676644B2 (en) | 2015-09-02 | 2020-04-08 | 久光製薬株式会社 | applicator |
US11103259B2 (en) | 2015-09-18 | 2021-08-31 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
BR112018012526B1 (en) * | 2015-12-21 | 2022-08-09 | Medrx Co., Ltd | MICRONEEDLE ADHESIVE APPLICATOR HOUSING, AND, MICRONEEDLE ADHESIVE APPLICATOR |
DK3851153T3 (en) * | 2016-04-29 | 2022-11-21 | Sorrento Therapeutics Inc | MICROCUNLE ARRAY ASSEMBLY AND MEDICATION DELIVERY DEVICE |
EP3554619B1 (en) | 2016-12-16 | 2021-10-20 | Sorrento Therapeutics, Inc. | Fluid delivery apparatus and method of assembly |
ES2943307T3 (en) | 2016-12-16 | 2023-06-12 | Sorrento Therapeutics Inc | Fluid delivery apparatus including a microneedle array suitable for treating a migraine or cluster headache |
ES2912537T3 (en) | 2016-12-16 | 2022-05-26 | Sorrento Therapeutics Inc | Support band for a fluid administration apparatus and method of use |
US11344709B2 (en) | 2016-12-16 | 2022-05-31 | Sorrento Therapeutics, Inc. | Fluid delivery apparatus having a controller assembly and method of use |
CA3047307A1 (en) | 2016-12-16 | 2018-06-21 | Sorrento Therapeutics, Inc. | Application device for a fluid delivery apparatus and method of use |
ES2960937T3 (en) | 2017-03-31 | 2024-03-07 | Vaxxas Pty Ltd | Device and method for coating surfaces |
WO2018227246A1 (en) | 2017-06-13 | 2018-12-20 | Vaxxas Pty Limited | Quality control of substrate coatings |
US11452466B2 (en) | 2017-06-19 | 2022-09-27 | Dexcom, Inc. | Applicators for applying transcutaneous analyte sensors and associated methods of manufacture |
CA3071680A1 (en) | 2017-08-04 | 2019-02-07 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map) |
EP3675935B1 (en) | 2017-08-30 | 2021-08-04 | Pirouette Medical LLC | Compact auto-injector |
US10441714B2 (en) | 2017-10-05 | 2019-10-15 | Pirouette Medical LLC | Protective case for an auto-injector |
CN112399908B (en) | 2018-06-25 | 2023-04-07 | 考里安公司 | Method of forming master mold, casting mold, and method of making microstructure array |
JP1632957S (en) | 2018-10-30 | 2019-06-03 | ||
AU2019414202B2 (en) * | 2018-12-25 | 2024-02-08 | Hirosaki University | Medicine administering device and medicine administering system |
DE102019200561A1 (en) * | 2019-01-17 | 2020-07-23 | Lts Lohmann Therapie-Systeme Ag | carrier |
DE102019200563A1 (en) * | 2019-01-17 | 2020-07-23 | Lts Lohmann Therapie-Systeme Ag | Applicator |
DE102019200558A1 (en) * | 2019-01-17 | 2020-07-23 | Lts Lohmann Therapie-Systeme Ag | Microarray recording |
DE102019200557A1 (en) * | 2019-01-17 | 2020-07-23 | Lts Lohmann Therapie-Systeme Ag | Applicator |
KR102368260B1 (en) * | 2020-01-09 | 2022-03-02 | 연세대학교 산학협력단 | Microneedle applicator |
CA3206301A1 (en) | 2021-09-28 | 2023-04-06 | George Albert Mansfield Iii | Microneedle enclosure and applicator device for microneedle array based continuous analyte monitoring device |
WO2024097385A1 (en) * | 2022-11-05 | 2024-05-10 | Kindeva Drug Delivery L.P. | Microneedle array applicator and system |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
WO1999029298A2 (en) | 1997-12-11 | 1999-06-17 | Alza Corporation | Device for enhancing transdermal agent flux |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US6312612B1 (en) | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
DE60024312T2 (en) | 1999-12-10 | 2006-08-17 | Alza Corp., Mountain View | Transdermal drug delivery of macromolecular agents and device therefor |
US6537242B1 (en) * | 2000-06-06 | 2003-03-25 | Becton, Dickinson And Company | Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance |
DE60136951D1 (en) | 2000-10-13 | 2009-01-22 | Alza Corp | MICROPHONE ELEMENT HOLDER FOR IMPACTOR |
HUP0303583A2 (en) | 2000-10-13 | 2004-01-28 | Alza Corp | Microblade array impact applicator |
WO2002030301A1 (en) | 2000-10-13 | 2002-04-18 | Alza Corporation | Apparatus and method for piercing skin with microprotrusions |
AU2001297823B2 (en) * | 2000-10-26 | 2005-05-12 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
DE60223844T2 (en) * | 2001-12-20 | 2008-08-28 | Alza Corp., Mountain View | MICROPROPERTIES FOR THROUGHPING THE SKIN WITH PILLAR DEPTH CONTROL |
DK1478428T3 (en) | 2002-02-04 | 2009-09-14 | Becton Dickinson Co | Device and method for delivering or withdrawing a substance through the skin |
US7097631B2 (en) | 2003-10-31 | 2006-08-29 | Alza Corporation | Self-actuating applicator for microprojection array |
WO2005065765A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Medical devices and kits including same |
WO2007001430A2 (en) | 2004-10-22 | 2007-01-04 | U.S. Department Of Veterans Affairs | Disimmortalizable mammalian chromaffin cell lines for cell therapy for pain |
JP2008520369A (en) | 2004-11-18 | 2008-06-19 | スリーエム イノベイティブ プロパティズ カンパニー | Inconspicuous microneedle array applicator |
US20080009811A1 (en) | 2004-11-18 | 2008-01-10 | 3M Innovative Properties Company | Non-Skin-Contacting Microneedle Array Applicator |
JP4927752B2 (en) | 2004-11-18 | 2012-05-09 | スリーエム イノベイティブ プロパティズ カンパニー | Microneedle array applicator and holding device |
US20060253078A1 (en) * | 2005-04-25 | 2006-11-09 | Wu Jeffrey M | Method of treating skin disorders with stratum corneum piercing device |
EP1904158B1 (en) | 2005-06-24 | 2013-07-24 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
WO2007002522A1 (en) | 2005-06-27 | 2007-01-04 | 3M Innovative Properties Company | Microneedle cartridge assembly and method of applying |
JP5144510B2 (en) * | 2005-06-27 | 2013-02-13 | スリーエム イノベイティブ プロパティズ カンパニー | Microneedle array application device |
EP1928537B1 (en) | 2005-09-02 | 2015-01-21 | Intercell USA, Inc. | Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs |
US7658728B2 (en) * | 2006-01-10 | 2010-02-09 | Yuzhakov Vadim V | Microneedle array, patch, and applicator for transdermal drug delivery |
WO2007124411A1 (en) | 2006-04-20 | 2007-11-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
US8821446B2 (en) * | 2007-01-22 | 2014-09-02 | Corium International, Inc. | Applicators for microneedles |
US8911749B2 (en) | 2007-04-16 | 2014-12-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
WO2008130587A2 (en) | 2007-04-16 | 2008-10-30 | Corium International, Inc. | Solvent-cast microneedle arrays containing active |
RU2569029C2 (en) | 2010-05-04 | 2015-11-20 | Кориум Интернэшнл, Инк. | Microneedle applicators |
-
2011
- 2011-05-04 RU RU2012151843/14A patent/RU2569029C2/en active
- 2011-05-04 EP EP11778276.3A patent/EP2566568B1/en active Active
- 2011-05-04 US US13/100,924 patent/US9687640B2/en active Active
- 2011-05-04 WO PCT/US2011/035221 patent/WO2011140240A2/en active Application Filing
- 2011-05-04 MX MX2012012815A patent/MX351458B/en active IP Right Grant
- 2011-05-04 JP JP2013509227A patent/JP5968875B2/en active Active
- 2011-05-04 CN CN201180032893.2A patent/CN102971038B/en active Active
- 2011-05-04 CA CA2801247A patent/CA2801247C/en active Active
- 2011-05-04 AU AU2011248166A patent/AU2011248166B2/en active Active
- 2011-05-04 CN CN201610004430.XA patent/CN105662530B/en active Active
- 2011-05-04 BR BR112012028263-8A patent/BR112012028263B1/en active IP Right Grant
- 2011-05-04 KR KR1020127031746A patent/KR101808635B1/en active IP Right Grant
- 2011-05-04 ES ES11778276T patent/ES2734560T3/en active Active
-
2012
- 2012-11-01 IL IL222803A patent/IL222803A/en active IP Right Grant
- 2012-11-29 ZA ZA2012/09035A patent/ZA201209035B/en unknown
-
2017
- 2017-06-26 US US15/633,583 patent/US10946180B2/en active Active
-
2021
- 2021-02-25 US US17/185,746 patent/US11666740B2/en active Active
-
2023
- 2023-05-16 US US18/318,603 patent/US20230277829A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11666740B2 (en) | Applicators for microneedles | |
AU2019200645B2 (en) | Microprojection applicators | |
EP2968118B1 (en) | Microarray for delivery of therapeutic agent and methods of use | |
ES2939317T3 (en) | Multi-impact micro-spray applicators | |
EP2934660A1 (en) | Microarray for delivery of therapeutic agent and methods of use | |
CN105073180A (en) | Microneedle applicator comprising a counter assembly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- INCOMPLETE APPLICATION (PRE-EXAMINATION) |